

PCT



WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 207/16, 209/42, 209/44 C07D 209/52, 211/60, 217/26 C07D 277/06, A61K 31/40	A1	(11) International Publication Number: WO 93/13066 (43) International Publication Date: 8 July 1993 (08.07.93)
(21) International Application Number: PCT/US92/10772 (22) International Filing Date: 18 December 1992 (18.12.92) (30) Priority data: 07/812,905 20 December 1991 (20.12.91) US (71) Applicant: SYNTEX (U.S.A.) INC. [US/US]; 3401 Hillview Avenue, Palo Alto, CA 94304 (US). (72) Inventors: KRANTZ, Alexander ; 189 Coldstream Avenue, Toronto, Ontario M5N 1X7 (CA). TAM, Tim, Fat ; 6441 Longspur Road, Mississauga, Ontario L5N 6E4 (CA). CASTELHANO, Arlindo, Lucas ; 3174 Springcreek Crescent, Mississauga, Ontario L5N 4S2 (CA). NES-TOR, John, Joseph, Jr. ; 20937 Fairwoods Court, Cupertino, CA 95014 (US).	(74) Agents: CLARKE, Pauline, Ann et al.; Syntex (U.S.A.) Inc., 3401 Hillview Avenue, A2-200, Palo Alto, CA 94304 (US). (81) Designated States: AU, CA, FI, HU, JP, KR, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS



(57) Abstract

Compounds of formula (I) wherein R¹ is alkoxycarbonyl, aralkoxycarbonyl, optionally substituted aralkanoyl, optionally substituted aroyl, optionally substituted heterocyclylcarbonyl, optionally substituted aryloxyalkanoyl, or optionally substituted heterocyclyloxyalkanoyl; R² is hydrogen; R³ is alkyl optionally substituted by hydroxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl; R⁴ is optionally substituted aryl or optionally substituted aralkyl; R⁵ is hydrogen; R⁶ is hydroxy; or R⁵ and R⁶ together form oxo, and R⁷ is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h) and (i), wherein n is 0, 1 or 2; each R¹⁴ is independently hydroxy, alkyl, alkoxy, or phenyl; and R¹⁰ is alkoxycarbonyl or optionally substituted monoalkylcarbamoyl; as a single stereoisomer or as a mixture thereof; or as pharmaceutically acceptable salts thereof, are useful in treating disease-states which are alleviated by treatment with an HIV protease inhibitor.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5

10

-1-

Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as HIV-protease inhibitors

Field of the Invention

15 The present invention is directed to compounds, and their
pharmaceutically acceptable salts, which inhibit the protease enzyme encoded
by the human immunodeficiency virus (HIV), thereby being useful in the
prevention of infection by HIV, in the treatment of infection by HIV and in
the treatment of the resulting acquired immune deficiency syndrome (AIDS). It
20 also relates to pharmaceutical compositions containing the compounds or their
pharmaceutically acceptable salts.

BACKGROUND OF THE INVENTION

25 A retrovirus designated human immunodeficiency virus (HIV) is the
etiologically agent of the complex disease that includes progressive destruction
of the immune system, such as acquired immune deficiency syndrome or AIDS, and
degeneration of the central and peripheral nervous system. A common feature
of retrovirus replication is the extensive post-translational processing of
precursor polyproteins by a virally encoded protease to generate mature viral
30 proteins required for virus assembly and function. Interruption of this
processing prevents the production of normally infectious virus.

Current treatments for AIDS usually involve the administration of
compounds which may inhibit viral DNA synthesis, or which may prevent HIV from
penetrating the host cell. None of these current treatments for AIDS have
35 proven to be totally effective in treating and/or reversing the disease. In
addition, many of the compounds currently used to treat AIDS cause adverse
side effects including low platelet count, renal toxicity and bone marrow
cytopenia.

The compounds of formula (I) exhibit the ability to inhibit retroviral
40 proteases, in particular, HIV protease, thereby providing a method for
blocking retroviral replication, in particular, HIV replication, and,
consequently, a treatment for diseases caused by HIV infection having fewer or
no side effects when compared to current treatments.

45 Related Disclosures

Peptidyl derivatives are disclosed in several published patent
applications as being useful in inhibiting retroviral proteases, for example,
European Published Patent Application No. 0 498 680 (Sankyo); European
Published Patent Application No. 0 490 667 (Nippon Mining); European Published
50 Patent Application Nos. 0 401 676 and 0 401 675 (Bi -mega); European Published


-2-

- Patent Application No. 0 356 223 (Merck & Co., Inc.); European Published Patent Application No. 0 342 541 (Abbott Laboratories); European Published Patent Application No. 0 346 847 (Hoffmann-La Roche); and European Published Patent Application No. 0 200 406 (Kissel Pharmaceutical). The design and
- 5 synthesis of peptidyl derivatives as HIV protease inhibitors is discussed in several research articles, including, but not limited to the following: *Chem. Pharm. Bull* (1991), Vol. 39, No. 9, pp. 2465-2467; *Science* (1990), Vol. 247, pp. 454-456; *Biochemical and Biophysical Research Communications* (1991), Vol. 180, No. 1, pp. 181-185; *Science* (1989), Vol. 246, pp. 1149-1151; *J. Med. Chem.* (1990), Vol. 33, pp. 2687-2689; *Science* (1990), Vol. 248, pp. 358-361; *J. Med. Chem.* (1990), Vol. 33, pp. 1285-1288; *Biochemical and Biophysical Research Communications* (1990), Vol. 169, No. 1, pp. 310-314; *Biochemical and Biophysical Research Communications* (1989), Vol. 163, No. 2, pp. 980-987; and *Biochemical and Biophysical Research Communications* (1989), Vol. 159, No. 2,
- 15 pp. 420-425.

SUMMARY OF THE INVENTION

In one aspect, this invention provides compounds of formula (I):

20




25 wherein:

- R¹ is alkoxycarbonyl, aralkoxycarbonyl, optionally substituted aralkanoyl, optionally substituted aroyl, optionally substituted heterocyclylcarbonyl, optionally substituted aryloxyalkanoyl, optionally substituted carbamoyl or optionally substituted heterocyclyloxyalkanoyl;
- 30 R² is hydrogen;
- R³ is alkyl optionally substituted by hydroxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl;
- R⁴ is optionally substituted aryl or optionally substituted aralkyl;
- R⁵ is hydrogen;
- 35 R⁶ is hydroxy; or
- R⁵ and R⁶ together form oxo; and
- R⁷ is selected from the group consisting of:

40

45

-3-



wherein

n is 0, 1 or 2;

each R^{14} is independently hydroxy, alkyl, alkoxy or phenyl; and

R^{10} is alkoxycarbonyl or optionally substituted carbamoyl;


as single stereoisomers or as mixtures thereof; or as pharmaceutically acceptable salts thereof.

In another aspect, this invention provides a method of inhibiting HIV protease activity in a mammal, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I) as defined above, as a single stereoisomer, or as a mixture thereof; or a pharmaceutically acceptable salt thereof.

In another aspect, this invention provides a pharmaceutical composition useful in inhibiting HIV protease activity in a mammal, which composition comprises a therapeutically effective amount of a compound of formula (I) as defined above, as a single stereoisomer or as a mixture thereof; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

In another aspect, this invention provides processes for the preparation of compounds of formula (I), which processes comprise

a) reacting a compound of the formula




wherein G_3 is an amino-protecting group selected from the group consisting of *t*-butoxycarbonyl, 2-(naphth-1-yloxy)ethanoyl and benzyloxycarbonyl and R^2 , R^3 , and R^4 are as defined above, with a compound of the formula

$H - R^7$

-4-

wherein R^7 is as defined above, to form a compound of formula (I) wherein G_3 is as defined above; or

b) treating a compound of the formula




wherein R^2 , R^3 , R^4 , and R^7 are as defined above, with a compound of the formula




wherein R^1 is as defined above, to form a compound of formula (I); or

c) reacting a compound of the formula



wherein R^4 and R^7 are as defined above, with a compound of the formula



wherein G_3 , R^2 , and R^3 are as defined above and R^{16} is hydrogen or p-nitrophenyl, to form a compound of formula (I) wherein G_3 is as defined above; or

d) oxidizing a compound of formula (I) wherein R^5 is hydrogen and R^6 is hydroxy, to form a compound of formula (I) wherein R^5 and R^6 together form oxo; or

e) converting a compound of formula (I) to a pharmaceutically acceptable salt thereof; or


f) converting a pharmaceutically acceptable salt of a compound of formula (I) to the corresponding free compound of formula (I); or

g) converting a pharmaceutically acceptable salt of a compound of formula (I) to another pharmaceutically acceptable salt of a compound of formula (I).

In a further aspect, this invention provides for the preparation of compounds of formula (I), which process, in step a) or c) of the above process, further comprises

a) catalytically hydrogenating a compound of formula (I) wherein G_3 is an amino-protecting group selected from the group consisting of t-butoxycarbonyl, 2-(naphth-1-yloxy)ethanoyl and benzyloxycarbonyl and R^2 , R^3 , R^4 , and R^7 are as defined above, to form a compound of the formula

-5-



5

followed by

b) treating a compound of formula (L) wherein R^2 , R^3 , R^4 , and R^7 are as defined above, with a compound of the formula

10



wherein R^1 is as defined above, to form a compound of formula (I); optionally followed by

- c) oxidizing a compound of formula (I) wherein R^5 is hydrogen and R^6 is hydroxy, to form a compound of formula (I) wherein R^5 and R^6 together form oxo; or
- d) converting a compound of formula (I) to a pharmaceutically acceptable salt thereof; or
- e) converting a pharmaceutically acceptable salt of a compound of formula (I) to the corresponding free compound of formula (I); or
- f) converting a pharmaceutically acceptable salt of a compound of formula (I) to another pharmaceutically acceptable salt of a compound of formula (I).

25

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated:

- "Boc" refers to t-butoxycarbonyl.
- "CBZ" refers to benzyloxycarbonyl (carbobenzyloxy).
- "DCC" refers to *N,N'*-dicyclohexylcarbodiimide.
- "DMF" refers to *N,N*-dimethylformamide.
- "EDCI" refers to *N*-ethyl-*N'*-(3-dimethylaminopropyl)-carbodiimide.
- "HOBT" refers to 1-hydroxybenzotriazole.
- "Halo" refers to bromo, chloro or fluoro.
- "Alkyl" refers to a straight or branched chain monovalent radical consisting solely of carbon and hydrogen, containing no unsaturation and having from one to four carbon atoms, e.g., methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, 1,1-dimethylethyl (*t*-butyl), and the like.
- "Alkoxy" refers to a radical of the formula $-\text{OR}_x$ wherein R_x is alkyl as defined above, e.g., methoxy, ethoxy, *n*-propoxy, 1-methylethoxy, *n*-butoxy, *t*-butoxy, and the like.
- "Alkoxycarbonyl" refers to a radical of the formula $-\text{C}(\text{O})\text{R}_x$ wherein R_x is alkoxy as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, *n*-propoxycarbonyl, and *t*-butoxycarbonyl, and the like.

45

"Aryl" refers to the phenyl or naphthyl radical.

"Aroyl" refers to a radical of the formula $-C(O)R_1$ where R_1 is aryl as defined above, e.g., benzoyl or naphthoyl.

5 "Aralkyl" refers to a radical of the formula $-R_1R_2$ where R_1 is alkyl as defined above and R_2 is aryl as defined above, e.g., benzyl.

"Aryloxy" refers to a radical of the formula $-OR_1$ where R_1 is aryl as defined above, e.g., phenoxy, or naphthyloxy.

"Aralkoxy" refers to a radical of the formula $-OR_1$ where R_1 is aralkyl as defined above, e.g., benzyloxy or naphthylmethoxy.

10 "Aralkanoyl" refers to a radical of the formula $-C(O)R_1$ where R_1 is aralkyl as defined above, e.g., phenylethanoyl, phenylpropanoyl, and the like.

"Aralkoxycarbonyl" refers to a radical of the formula $-C(O)OR_1$ where R_1 is aralkyl as defined above, e.g., benzyloxycarbonyl or naphthylmethoxycarbonyl.

15 "Aryloxyalkanoyl" refers to a radical of the formula $-C(O)R_1OR_2$ where R_1 is alkyl as defined above and R_2 is aryl as defined above, e.g., naphth-1-yloxyethanoyl, phenoxyethanoyl, 2-(naphth-2-yloxy)propanoyl, and the like.

"Heterocyclyl" refers to a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocyclic ring radical which is either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein the nitrogen, carbon or sulfur atoms may optionally be oxidized, and the nitrogen atom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic ring radicals is fused to a benzene ring. The heterocyclic ring radical may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic radicals include, but are not limited to, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfide, thiamorpholinyl sulfone, and oxadiazolyl. Preferred heterocyclic radicals for the purposes of this invention are imidazolyl, piperazinyl, pyridyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, and decahydroisoquinolyl.

40 "Heterocyclylalkyl" refers to a radical of the formula $-R_1R_2$ where R_1 is alkyl as defined above and R_2 is heterocyclyl as defined above, e.g., quinol-2-ylmethyl, pyrid-2-ylmethyl, imidazol-1-ylmethyl, morpholin-4-ylmethyl, 4-methylpiperazin-1-ylmethyl, and the like.

45 "Heterocyclylcarbonyl" refers to a radical of the formula $-C(O)R_1$ where

R_1 is heterocyclyl as defined above, e.g., quinolylcarbonyl, octahydroindolylcarbonyl, and the like.

"Heterocyclyloxyalkanoyl" refers to a radical of the formula $-C(O)R_1OR_2$, where R_1 is alkyl as defined above and R_2 is heterocyclyl as defined above, e.g., 2-(quinolyl-2-yloxy)ethanoyl, and the like.

"Carbamoyl" refers to the radical $-C(O)NH_2$.

"Monoalkylcarbamoyl" refers to a radical of the formula $-C(O)NH(R_1)$ where R_1 is alkyl as defined above, e.g., *N*-methylcarbamoyl, *N*-ethylcarbamoyl, and the like.

"Dialkylcarbamoyl" refers to a radical of the formula $-C(O)N(R_1)_2$, where each R_1 is independently alkyl as defined above, e.g., *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N,N*-ethylmethylcarbamoyl, and the like.

"Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.

"Optionally substituted aryl" refers to a phenyl or naphthyl group optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, alkoxy, hydroxy, and nitro, e.g., 4-nitrophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 3-hydroxyphenyl, and the like.

"Optionally substituted aralkyl" refers to an aralkyl radical, as defined above, wherein the phenyl or naphthyl group thereof is optionally substituted by one or more substituents selected from the group consisting of halo, alkyl, alkoxy, hydroxy, and nitro, e.g., 4-hydroxybenzyl, 3,5-dichlorophenylethyl, 6-methoxynaphthylmethyl, and the like.

"Optionally substituted aralkanoyl" refers to aralkanoyl radicals, as defined above, wherein the phenyl or naphthyl group thereof is optionally substituted by one or more substituents selected from group consisting of halo, alkyl, alkoxy, hydroxy, and nitro, e.g., 2-(4-bromonaphth-2-yl)-ethanoyl, 2-(6-methoxynaphth-1-yl)ethanoyl, and the like.

"Optionally substituted aroyl" refers to aroyl radicals, as defined above, wherein the phenyl or naphthyl group thereof is optionally substituted by one or more substituents selected from a group consisting of halo, alkyl, alkoxy, hydroxy and nitro, e.g., 4-bromobenzoyl, 2-(3,5-dichlorophenyl)ethanoyl, and the like.

"Optionally substituted aryloxyalkanoyl" refers to a aryloxyalkanoyl radical, as defined above, wherein the phenyl or naphthyl group thereof is optionally substituted by one or more substituents independently selected from the group consisting of halo, alkyl, alkoxy, hydroxy, nitro, and heterocyclylalkyl, as defined above. Examples include, but are not limited to 2-(6-bromonaphth-1-yl)oxyethanoyl, 2-(4-methoxy-phenoxy)ethanoyl, 2-(3-(m rph lin-4-ylmethyl)phenoxy)ethanoyl, 2-(3-(4-methylpiperazinylmethyl)-phenoxy)ethanoyl, 2-(3-(imidazol-1-ylmethyl)phenoxy)ethanoyl, and the like.

"Optionally substituted heterocyclylcarbonyl" refers to a heterocyclylcarbonyl radical, as defined above, wherein the heterocyclyl group thereof is optionally substituted by one or more substituents selected from the group consisting of halo, alkyl and alkoxy, e.g., 4-bromoquinol-2-ylcarbonyl, and the like.

"Optionally substituted heterocyclyloxyalkanoyl" refers to a heterocyclyloxyalkanoyl radical, as defined above, wherein the heterocyclyl group thereof is optionally substituted by one or more substituents selected from the group consisting of halo, alkyl and alkoxy, e.g., 2-(6-bromoquinol-2-yloxy)ethanoyl, or 2-(8-methoxyquinol-2-yloxy)ethanoyl, and the like.

"Optionally substituted carbamoyl" refers to a carbamoyl radical, as defined above, wherein the nitrogen atom thereof is optionally substituted by an alkyl group, a heterocyclyl group, or a heterocyclylalkyl group as defined above. If present, the alkyl group may be optionally substituted by hydroxy, e.g., 1-hydroxy-2-methylprop-2-yl, and the like. Examples include, but are not limited to, *N*-(1-hydroxy-2-methylprop-2-yl)carbamoyl, *N*-methyl-*N*-(pyridin-2-ylmethyl)carbamoyl, and the like.

"Amino-protecting group" as used herein refers to those organic groups intended to protect nitrogen atoms against undesirable reactions during synthetic procedures, and includes, but is not limited to, benzyl, acyl, acetyl, benzyloxycarbonyl (carbobenzyloxy), *p*-methoxybenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl, *t*-butoxycarbonyl, and the like.

"Pharmaceutically acceptable salt" includes both acid and base addition salts.

"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, salicylic acid, and the like.

"Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamin, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, trimethamine,

dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, *N*-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, 5 diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline and caffeine.

"Mammal" includes humans and all domestic and wild animals, including, without limitation, cattle, horses, swine, sheep, goats, dogs, cats, and the like.

10 "Therapeutically effective amount" refers to that amount of a compound of formula (I) which, when administered to a mammal in need thereof, is sufficient to effect treatment, as defined below, for disease-states alleviated by inhibition of HIV protease. The amount of a compound of formula (I) which constitutes a "therapeutically effective amount" will vary depending 15 on the compound, the disease-state and its severity, and the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.

"Treating" or "treatment" as used herein cover the treatment of a disease-state in a mammal, particularly in a human, which disease-state is 20 alleviated by inhibition of HIV protease, e.g., AIDS, ARC, HIV infection, and the like; and include:

- (i) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it;
- 25 (ii) inhibiting the disease-state, i.e., arresting its development; or
- (iii) relieving the disease-state, i.e., causing regression of the disease-state.

"Stereoisomers" refers to compounds having identical molecular formulae and nature or sequence of bonding but differing in the arrangement of their 30 atoms in space.

The nomenclature used herein is basically a modified form of I.U.P.A.C. nomenclature wherein compounds of the invention are named as derivatives of the R^7 moiety, e.g., prolinamide, octahydroindolecarboxamide, decahydroquinolinecarboxamide, octahydroisoindolecarboxamide, and the like.


35 The compounds of formula (I), or their pharmaceutically acceptable salts, have at least two asymmetric carbon atoms in their structure, one to which R^4 is attached and the other to which R^5 and R^6 are attached. In addition, certain R^7 substituents may also contain asymmetric carbon atoms. The compounds of formula (I) and their pharmaceutically acceptable salts may 40 therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of this invention.

When naming the single stereoisomers of compounds of formula (I) an absolute descriptor, *R* or *S*, may be assigned to the chiral carbon atoms 45 therein according to the "Sequence Rule" procedure of Cahn, Ingold and Prelog. Stereoisomers of compounds of formula (I) wherein the carbon to which R^4 is

-10-


attached and the carbon to which R⁵ and R⁶ are attached are both in the "S" configuration are particularly preferred. In addition, those sections of compounds of formula (I) which includes R³, together with the nitrogen atom and carbonyl group to which it is attached, may define an α -amino acid residue and are named as such. For example, a compound of formula (I) wherein R¹ is 2-(naphth-1-yloxy)ethanoyl; R² is hydrogen; R³ is carbamoylmethyl; R⁴ is benzyl; R⁵ is hydrogen; R⁶ is hydroxy; and R⁷ is

10



15 where R¹⁰ is *N*-*t*-butylcarbamoyl; i.e., a compound of the following formula:

20



25

is named herein as (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl)-L-asparaginyl]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N*'-*t*-butylcarboxamide.

30

Utility and Administration

A. Utility

The compounds of formula (I) are useful in the inhibition of the protease virally encoded by the human deficiency virus (HIV), thereby preventing production of the virus. The compounds of formula (I) are therefore useful in treating disease-states which are alleviated by the inhibition of HIV protease, such as Acquired Immune Deficiency Syndrome (AIDS) and AIDS Related Complex (ARC). In addition, the compounds of formula (I) prevent infection by HIV by not allowing the virus to replicate within the cells of the body after initial exposure to HIV, e.g., by a blood transfusion, an accidental needle stick, or exposure to patient blood.

B. Testing

The ability of the compounds of formula (I) to inhibit HIV protease or the production of HIV can be demonstrated by a variety of *in vitro* assays that are known to those of ordinary skill in the art, such as the *in vitro* assay

45

described in *Biochem. Biophys. Res. Commun.* (1989), Vol. 164, pp. 955-960, or a modification thereof; or the *in vitro* cell assay described in *Biochem. Pharmacol.* (1987), Vol. 36, pp. 4361-2.

C. General Administration

5 Administration of the compounds of formula (I), or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally, topically, 10 transdermally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The compositions will 15 include a conventional pharmaceutical carrier or excipient and a compound of formula (I) as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by 20 weight of a compound(s) of formula (I), or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. Preferably, the composition will be about 5% to 75% by weight of a compound(s) of formula (I), or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.

25 The preferred route of administration is oral, using a convenient daily dosage regimen which can be adjusted according to the degree of severity of the disease-state to be treated. For such oral administration, a pharmaceutically acceptable composition containing a compound(s) of formula (I), or a pharmaceutically acceptable salt thereof, is formed by the 30 incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, 35 capsules, powders, sustained release formulations and the like.

Preferably such compositions will take the form of capsule, caplet or tablet and therefore will also contain a diluent such as lactose, sucrose, dicalcium phosphate, and the like; a disintegrant such as croscarmellose sodium or derivatives thereof; a lubricant such as magnesium stearate and the 40 like; and a binder such as a starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose ether derivatives, and the like.

The compounds of formula (I), or their pharmaceutically acceptable salts, may also be formulated into a suppository using, for example, about 0.5% to about 50% active ingredient disposed in a carrier that slowly 45 dissolves within the body, e.g., polyoxyethylene glycols and polyethylene glycols (PEG), e.g., PEG 1000 (96%) and PEG 4000 (4%).

-12-

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., a compound(s) of formula (I) (about 0.5% to about 20%), or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension.

If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.

Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, 18th Ed., (Mack Publishing Company, Easton, Pennsylvania, 1990). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, for treatment of a disease-state alleviated by the inhibition of HIV protease in accordance with the teachings of this invention.

The compounds of formula (I), or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. Generally, a therapeutically effective daily dose is from about 0.14 mg to about 14.3 mg/kg of body weight per day of a compound of formula (I), or a pharmaceutically acceptable salt thereof; preferably, from about 0.7 mg to about 10 mg/kg of body weight per day; and most preferably, from about 1.4 mg to about 7.2 mg/kg of body weight per day. For example, for administration to a 70 kg person, the dosage range would be from about 9.8 mg to about 1.0 gram per day of a compound of formula (I), or a pharmaceutically acceptable salt thereof, preferably from about 50 mg to about 700 mg per day, and most preferably from about 100 mg to about 500 mg per day.

Preferred Embodiments


A preferred group of the compounds of formula (I), as described above in the Summary of the Invention, are those compounds wherein the carbon to which R⁴ is attached is in the S-configuration and the carbon to which R¹ and R⁶ are attached is in the S-configuration; and wherein R¹ is aralk xycarbonyl, optionally substituted aryloxyalkanoyl, optionally substituted carbamoyl or optionally substituted heterocyclylcarbonyl; R³ is alkyl optionally substituted by carbamoyl; R⁴ is optionally substituted aralkyl; R⁵ is hydrogen;

-13-

R⁶ is hydroxy; and

R⁷ is selected from the group consisting of:

5



wherein

10 R¹⁰ is monoalkylcarbamoyl.

A preferred subgroup of this group of compounds are those compounds wherein R¹ is optionally substituted aryloxyalkanoyl; R³ is 1-methylethyl or methyl substituted by carbamoyl; and R⁴ is benzyl. Within this subgroup of compounds, more preferred are those compounds wherein R¹ is 2-(naphth-1-yloxy)ethanoyl or 2-phenoxyethanoyl.

15

Another preferred subgroup of compounds are those compounds wherein R¹ is optionally substituted heterocyclylcarbonyl; R³ is 1-methylethyl or methyl substituted by carbamoyl; and R⁴ is benzyl. Within this subgroup, more preferred are those compounds wherein R¹ is quinol-2-ylcarbonyl.

20

Another preferred subgroup of compounds are those compounds wherein R¹ is optionally substituted carbamoyl; R³ is 1-methylethyl or methyl substituted by carbamoyl; and R⁴ is benzyl. Within this subgroup, more preferred compounds are those compounds wherein R¹ is *N*-methyl-*N*-(pyridin-2-ylmethyl)carbamoyl.

25

Presently, the most preferred compounds of formula (I) are the following:

(2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide;
 (1*S*,3*aR*,7*aS*)-2-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroisindole-1-*N'*-*t*-butylcarboxamide;
 30 (1*S*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroisindole-1-*N'*-*t*-butylcarboxamide;
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide;
 35 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*iso*-propylcarboxamide;
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-phenoxyethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide;
 40 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide;
 (1*S*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroisindole-1-*N'*-*t*-butylcarboxamide;
 (1*S*,3*S*,5*S*)-*N*-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-

-14-

- 2-hydroxy-4-phenylbutanoyl)]-2-azabicyclo[3.3.0]octane-3-N'-t-butylcarboxamide;
 (2S,3aS,7aS)-1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide; and
 5 (2S,3aS,7aS)-1-[(2S,3S)-3-(N"-methyl-N"-(pyridin-2-ylmethyl)carbamoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide.

Preparation of Compounds of Formula (I)

- 10 Compounds of formula (I), as single stereoisomers, or as mixtures thereof, and their pharmaceutical acceptable salts, are peptide derivatives which can be prepared from the constituent α -amino acids. Standard methods for the formation of peptide bonds are further illustrated by M. Bodanszky et al., *The Practice of Peptide Synthesis* (1984), Springer-Verlag; M. Bodanszky,
 15 *Principles of Peptide Synthesis* (1984), Springer-Verlag; J.P. Greenstein et al., *Chemistry of the Amino Acids* (1961), Vol. 1-3, John Wiley and Sons Inc.; G.R. Pettit, *Synthetic Peptides* (1970), Vol. 1-2, Van Nostrand Reinhold Company.

- Amide couplings used to form the compounds of formula (I) are generally
 20 performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide (DCC), or N'-ethyl,N'-(3-dimethylaminopropyl)-carbodiimide (EDCI) in the presence of 1-hydroxybenzotriazole (HOST) in an inert solvent such as dimethylformamide (DMF). Other methods of forming the amide or
 25 peptide bond include, but are not limited to, synthetic routes via an acid chloride, acyl azide, mixed anhydride or activated ester such as nitrophenyl ester. Typically, solution phase amide couplings with or without peptide fragments are performed.

- The selection of protecting groups for the terminal amino or carboxy groups of compounds used in the preparation of the compounds of formula (I) is
 30 dictated in part by the particular amide or peptide coupling conditions, and in part by the amino acid and/or peptide components involved in the coupling. Amino-protecting groups commonly used include those which are well-known in the art, for example, benzyloxycarbonyl (carbobenzyloxy), p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, t-butoxycarbonyl (Boc), and the like.
 35 It is preferred to use either Boc or benzyloxycarbonyl ("CBZ") as the protecting group for the α -amino group because of the relative ease of its removal by mild acids, e.g., by trifluoroacetate acid ("TFA") or hydrochloric acid in ethyl acetate; or by catalytic hydrogenation.

- The individual stereoisomers of compounds of formula (I) may be
 40 separated from each other by methods known to those of ordinary skill in the art, e.g., by selective crystallization or by chromatography, and/or by the methods disclosed herein.

- When any variable, e.g., R¹, R¹⁰ or G, occurs more than once in any substituent or in any formula described herein, its definition on each
 45 occurrence, unless specified otherwise, is independent of its definition at every other occurrence. Combinations of substituents and/or variables are


-15-

permissible only if such combinations result in stable compounds.

A. Preparation of Starting Materials: Compounds of formula (F).

Compounds of the following formula (F);


5



where R⁴ is optionally substituted aryl or optionally substituted aralkyl, preferably benzyl; R⁵ is hydrogen, R⁶ is hydroxy, and R¹⁵ is alkyl are used in the preparation of compounds of formula (I) and are prepared as shown in the following Reaction Scheme 1a where R⁴ is optionally substituted aryl or optionally substituted aralkyl, preferably benzyl; R¹⁵ is alkyl, X is bromo or chloro and each G_i group is the same and is benzyl:

15

-16-

Reaction Scheme 1a

Compounds of formula (Fa) used in Step 1 of Reaction Scheme 1a, for example, phenylalaninol, tyrosin 1 and the like, are commercially available, for example, from Aldrich Company, or may be prepared by methods known to those of ordinary skill in the art. Preferably, in Reaction Scheme 1a, compounds of

formula (Fa) are such that the carbon to which the R⁴ substituent is attached is in the "S" configuration.

Compounds of the formula R¹⁵OH used in steps 4a and 4b of Reaction Scheme 1a, for example, methanol and ethanol, are commercially available, for example, from Aldrich Company, or may be prepared by methods known to those of ordinary skill in the art.

Compounds of formula (Fb), for example, benzyl bromide and benzyl chloride, used in step 1 of Reaction Scheme 1a, are commercially available, for example, from Aldrich Company, or may be prepared by methods known to those of ordinary skill in the art.

In general, a compound of formula (F) is prepared by the process described by Reaction Scheme 1a by first treating a compound of formula (Fa) with 2.2 to 2.5 molar equivalents of a compound of formula (Fb) in the presence of a base, preferably potassium carbonate, in refluxing water for a period of 1 to 5 hours, preferably for four hours. The resulting solution is then cooled and the compound of formula (Fc) is then isolated from the solution by conventional isolation techniques, for example, by extraction followed by chromatography (Step 1).

In Step 2 a compound of formula (Fc) in an inert solvent, for example, methylene chloride, is treated with an oxidizing agent, preferably, oxalyl chloride and methyl sulfoxide in an inert solvent, for example, methylene chloride, at initial temperatures of below -60°C. The resulting solution is allowed to warm to room temperature and the corresponding compound of formula (Fd) is then isolated from the solution by conventional isolation techniques, for example, by extraction and chromatography.

Compounds of formula (Fe) are prepared in Step 3 according to the procedure described in *Tetrahedron Letters* (1988), pp. 3295-3298, by M.T. Reetz, M.M. Drewes, K. Harms and W. Reif. In particular, a compound of formula (Fd) in an inert solvent, preferably methylene chloride, is added to a suspension of equimolar amount of ZnBr₂ in an inert solvent, preferably methylene chloride, at -30°C to about -10°C, preferably at -20°C. After about 15 to 40 minutes, preferably after about 30 minutes, trimethylsilyl cyanide is added to the ZnBr₂ solution. The resulting mixture is stirred at -30°C to about -10°C, preferably at -20°C for about 3 to 5 hours, preferably for about 4.5 hours. The compound of formula (Fe) is then isolated from the reaction mixture by conventional isolation techniques, for example, by extraction with an organic solvent, for example, ethyl acetate. HPLC analysis indicates that the compound of formula (Fe) is formed as two distinct diastereomers, i.e., a (2S,3S) diastereomer and a (2R,3S) diastereomer, in a 95:5 ratio, respectively.

The compound of formula (Fe) is then treated with a compound of formula R¹⁵OH, for example, ethanol or methanol, under acid hydrolysis conditions to form a compound of formula (Ff) (Step 4a). The preferred conditions for this hydrolysis involve the bubbling of hydrogen chloride gas into an anhydrous protic solvent, for example, a 3:1 mixture of ether and ethanol, at low temperatures, for example, 0°C. Normally, 8 to 10 mL of the 3:1 mixture of

-18-


anhydrous ether and absolute ethanol is used for every gram quantity of compound of formula (Fe). A compound of formula (Fe) in a protic solvent, preferably anhydrous ether, is then added to this solution. The resulting mixture is stirred at about 5°C for about 20 to about 28 hours, preferably for about 24 hours. Ice-cold water (0.6 to 0.8 mL per gram of compound of formula (Fe)) is then added to this mixture, which is then stirred for 2 to 3 days, preferably for about 2 days, at about 5°C. The mixture is then neutralized by the addition of base, preferably a mixture of sodium bicarbonate and ethyl acetate. A compound of formula (Ff) and its corresponding amide are then isolated from the neutralized reaction mixture by conventional techniques, for example, by filtration, extraction, and chromatography.

Alternatively, a compound of formula (Ff) may be prepared by the process described by Step 4b of Reaction Scheme 1a. For example, a compound of formula (Fe) is treated with an acid, preferably concentrated hydrochloric acid, at refluxing temperatures for a period of 12 to 20 hours, preferably for about 16 hours. The pH of the resulting mixture is then adjusted with base to about pH 4. The compound of formula (Fg) is then isolated from the reaction mixture by conventional techniques, for example, extraction and chromatography, and then treated with an acidic solution of a compound of formula $R^{14}OH$, preferably a solution of ethanol saturated with hydrogen chloride gas, at room temperature for about 24 hours. The solvent is then removed from the reaction mixture, which is neutralized by base as described above. The compound of formula (Ff) is then isolated from the reaction mixture by conventional methods of extraction.

The amino-protecting groups of the compounds of formula (Ff), i.e., the G_1 substituents, are removed by catalytic hydrogenation, for example, by hydrogenating an ethanolic solution of a compound of formula (Ff) over 20% Pd(OH)₂/C at 50 psi H₂ over a period of 16 to 24 hours, preferably over a period of 20 hours, to give a compound of formula (F). The preferred conditions are to employ 0.4 gram of the 20% Pd(OH)₂/C catalyst to each gram of compound of formula (Ff) used.

Alternatively, compounds of formula (F) can be prepared from compounds of formula (E) as illustrated below in Reaction Scheme 1b wherein R^4 is benzyl; R^{15} is alkyl; and G_1 is benzyloxycarbonyl:

Reaction Scheme 1b



Compounds of formula (E) may be prepared according to the procedures described in R. Herranz et al., *J. Org. Chem.* (1990), Vol. 55, pp. 2232-2234; R. Herranz et al., *Synthesis* (1989), pp. 703-706; R. Nishizawa et al., *J. Org.*

Chem. (1977), Vol. 20, pp. 510-515; F. Matsuda et al., Chem. Letts. (1990), pp. 723-724; H. Harada et al., Chem. Pharm. Bull. (1989), Vol. 37, No. 9, pp. 2570-2572; K. Iizuka et al., J. Chem. Soc., Chem. Comm. (1989), pp. 1678-1680; Y. Ito et al., Heterocycles (1990), Vol. 30, pp. 299-302; Y. Kobayashi et al., Chem. Letts. (1990), pp. 1709-1710; K. Iizuka et al., J. Med. Chem. (1990), Vol. 33, pp. 2707-2714; D.H. Rich et al., J. Org. Chem. (1980), Vol. 45, pp. 2288-2290; R.L. Johnson, J. Med. Chem. (1982), Vol. 25, pp. 605-610.

Preferably, for the purposes of Reaction Scheme 1b, the compounds of formula (E) are such that the carbon to which the hydroxy is attached is in the "S" configuration, and that the carbon to which the R' substituent is attached is also in the "S" configuration.

The amino-protecting group of a compound of formula (E), i.e., the G₂ substituent, is removed by catalytic hydrogenation, for example, a solution of a compound of formula (E) in alcohol, preferably methanol or ethanol, is hydrogenated over 10% Pd/C at 50 psi H₂ for 6 to 12 hours, preferably, for about 8 hours. The compound of formula (F) is then isolated from the reaction mixture by conventional methods.

B. Preparation of Compounds of Formula (Ia) and (I)


Compounds of formula (Ia) are compounds of formula (I) wherein R¹ is G₂, an amino-protecting group selected from the group consisting of t-butoxycarbonyl, 2-(naphth-1-yloxy)ethanoyl and benzyloxycarbonyl; R², R³, R⁴ and R⁷ are as defined above in the Summary of the Invention; R⁵ is hydrogen and R⁶ is hydroxy.

Compounds of formula (Ib) are compounds of formula (I) wherein R¹, R², R³, R⁴ and R⁷ are as defined above in the Summary of the Invention; and R⁵ is hydrogen and R⁶ is hydroxy.


Compounds of formulae (Ia) and (Ib) are prepared as shown in the following Reaction Scheme 2 where R¹⁵ is alkyl and R¹⁶ is hydrogen or p-nitrophenyl:

-20-

Reaction Scheme 2




10




15

20




25

30



35



40

Compounds of formula (G) used in Step 1 of Reaction Scheme 2 are commercially available, for example, benzyloxycarbonyl-L-asparagine
 45 p-nitrophenyl ester, t-butoxycarbonyl-L-asparagine p-nitrophenyl ester, benzyloxycarbonyl L-valine. Other compounds of formula (G), such as

benzyloxycarbonyl-N',N'-diethyl-L-asparagine, may be prepared by methods known in the art or by the method illustrated in Preparation 9 below.

Compounds of formula (K) used in Step 3 of Reaction Scheme 2 are prepared according to standard procedures in the peptide literature, e.g., M. Bodansky, A. Bodansky, *The Practice of Peptide Synthesis*, Springer-Verlag, 1984. For example, t-butoxycarbonyl-L-proline reacts with t-butylamine under standard peptide coupling conditions such as isobutylchloroformate, N-methylmorpholine or EDCI/HOBT in an inert solvent such as EDCI to give t-butoxycarbonyl-N'-t-butyl-L-prolinamide. The t-butoxycarbonyl group can be removed by treating this compound with HCl gas in dry methylene chloride for a period of 1 to 3 hours, preferably for 1 hour. Removal of the solvent yields N'-t-butyl-L-prolinamide hydrochloride which can be neutralized with base such as triethylamine in methylene chloride to give the free amine, N'-t-butyl-L-prolinamide, i.e., a compound of formula (K).

Alternatively, when a benzyloxycarbonyl derivative is used, for example, benzyloxycarbonyl-N'-t-butyl-L-(4R)-hydroxyprolinamide (prepared under similar conditions as described above), the benzyloxycarbonyl group is removed by catalytic hydrogenation. For example, a solution of benzyloxycarbonyl-N'-t-butyl-L-(4R)-hydroxyprolinamide in absolute ethanol is hydrogenated at 50 psi H₂ over 10% Pd/C to give the free amine, N'-t-butyl-L-(4R)-hydroxyprolinamide, i.e., a compound of formula (K).

In a similar manner other compounds of formula (K) can be prepared, e.g., octahydroindole-2-N'-t-butylcarboxamide, octahydroisindole-3-N'-t-butylcarboxamide, or N'-t-butyl-L-(4S)-hydroxyprolinamide. Furthermore, the synthesis of individual stereoisomers of an octahydroindoline amino acid was reported in *Tetrahedron Letters*, Vol. 31, No. 34, pp. 4889-4892 and in *Drug Design and Discovery* (1992), Vol. 9, pp. 11-28; and the synthesis of an individual stereoisomer of an azobicyclo[3.3.0]octane amino acid was reported in *Heterocycles* (1989), Vol. 28, p. 957. These examples are for illustrative purposes only and shall not be viewed as limitations on the scope of the invention described herein.

Compounds of formula (M) used in Step 5 of Reaction Scheme 2 are commercially available, for example, 1-naphthoxyacetic acid, 2-naphthoxyacetic acid, quinoline-2-carboxylic acid, for example, from Aldrich Co., or may be prepared by methods known to those of ordinary skill in the art. For example, 6-bromo-2-naphthoxyacetic acid is prepared from ethyl bromoacetate, potassium carbonate and 6-bromo-2-naphthol in DMF, followed by base hydrolysis.

In general, a compound of formula (Ia) is prepared by treating a compound of formula (G), preferably, a compound of formula (G) where R¹⁶ is p-nitrophenyl, in an aprotic solvent, for example, tetrahydrofuran, for a period of up to four days, preferably for three days, at room temperature to form a compound of formula (H) (Step 1 of Reaction Scheme 2).

Alternatively, compounds of formula (H) may be prepared by their peptide couplings, for example, a compound of formula (G) where R¹⁶ is hydrogen can be treated with 1.1 molar equivalents of HOBT and, preferably, about 2.0 to about

-22-

2.5 molar equivalents of EDCI in an aprotic solvent, preferably DMF, under an inert atmosphere, such as argon or nitrogen, at 0°C to about 5°C, for about 30 to about 60 minutes, preferably for about 45 minutes, to afford the activated ester. A molar equivalent amount of a compound of formula (F) in an aprotic solvent, for example, DMF, methylene chloride, or a combination of DMF and methylene chloride is then added to the activated ester in an aprotic solvent, for example, dimethylformamide. The resulting reaction mixture is then stirred at room temperature for about 12 to about 16 hours to afford a compound of formula (H).

10 A compound of formula (H) can then be hydrolyzed under base conditions, preferably with 1N sodium hydroxide in water/dioxane at 0°C for about 30 to 60 minutes, to give the free acid, i.e., a compound of formula (J) (Step 2 of Reaction Scheme 2).

15 A compound of formula (J) and a compound of formula (K) are then coupled under similar conditions as described above for the alternate preparation of compounds of formula (H), for example, with EDCI and HOBT in DMF, to afford a compound of formula (Ia) (Step 3 of Reaction Scheme 2).

20 Alternatively, other peptide couplings may be used to prepare compounds of formula (Ia). For example, the compound of formula (J) can be reacted with about 1 to 1.1 molar equivalent of *N*-methyloxymorpholine and about 1 to 1.1 molar equivalent of isobutylchloroformate at -10°C to -15°C in an inert solvent, for example, tetrahydrofuran (THF) or DMF, or a combination of both, to afford a mixed anhydride. Subsequent reaction of this mixed anhydride with a compound of formula (K) for 12 hours affords a compound of formula (Ia), which can be isolated from the reaction mixture by conventional isolation techniques standard in the art of peptide chemistry, for example, extraction, column chromatography, and/or HPLC.

25 The amino-protecting group of a compound of formula (Ia), i.e., the G₁ substituent, can be removed when G₁ is benzyloxycarbonyl by catalytic hydrogenation, for example, by reacting the compound with 10% Pd/C in absolute ethanol with 50 psi hydrogen, to afford a compound of formula (L) (Step 4 of Reaction Scheme 2).

30 Compounds of formula (L) are then coupled with compounds of formula (M) under similar conditions as described above for the preparation of compounds of formula (Ia), for example, with EDCI and HOBT in DMF, to afford compounds of formula (Ib) (Step 5 of Reaction Scheme 2).


40 Compounds of formulae (Ia) and (Ib) can further be oxidized by an oxidizing agent, for example, pyridinium dichromate in DMF/CH₂Cl₂, or by the methods described in, for example, J.G. Moffat, et al., *J. Am. Chem. Soc.*, Vol. 87, pp. 5661-5669 and 5670-5678, to form compounds of formula (I) wherein R⁵ and R⁶ together form oxo.

C. Alternate Method of Preparation of Compounds of Formula (Ia)

45 Compounds of formula (Ia) are alternately prepared as shown in the following Reaction Scheme 3 where R¹, R², R³, R⁴ and R⁷ are as defined above in the Summary of the Invention; R¹⁶ is hydrogen or *p*-nitrophenyl; each G_i is the same

amino-protecting group selected from the group consisting of *t*-butoxycarbonyl, 2-(naphth-1-yloxy)ethanoyl and benzyloxycarbonyl; and each G_4 is benzyl or one G_4 is benzyloxycarbonyl and the other G_4 is hydrogen:

Reaction Scheme 3



25

Compounds of formula (K) may be prepared by the methods described earlier in Reaction Scheme 2, or by methods known to those of ordinary skill in the art.

30 Compounds of formula (Fg) where each G_4 is benzyl are prepared as described above in Reaction Scheme 1a. Compounds of formula (Fg) where one G_4 is benzyloxycarbonyl and the other G_4 is hydrogen are prepared from the corresponding amino acid which has been treated with trimethylsilyl cyanide followed by benzyl chloroformate, as described in Preparation 7E below. Preferably, for the purposes of Reaction Scheme 3, the compounds of formula

35 (Fg) are such that the carbon to which the R^4 substituent is attached is in the *S*-configuration, and that the carbon to which the hydroxy group is attached is also in the *S*-configuration.

Compounds of formula (G) are *N*-protected α -amino acids that are commercially available, for example, from Aldrich Co., or may be prepared by

40 methods known to one of ordinary skill in the art.

In general, a compound of formula (Ia) may be prepared by the process described by Reaction Scheme 3 by first reacting a compound of formula (K) with a compound of formula (Fg) wherein both G_4 groups are benzyl under standard peptide coupling conditions known in the art. For example, a

45 solution of a compound of formula (Fg) and an equimolar amount of HOBT in an

inert solvent, preferably DMF, is cooled to about 0°C. An equimolar amount of EDCI is then added to the cooled solution and the resulting mixture is stirred at about 0°C for about 40 to about 60 minutes, preferably for about 40 minutes. A compound of formula (K) in an inert solvent, preferably methylene chloride, is then added to this solution, and the resulting mixture is then stirred at room temperature for about 20 to about 26 hours, preferably for about 24 hours. A compound of formula (N) is then isolated from the solution by conventional methods, for example, by extraction and chromatography (Step 1 of Reaction Scheme 3).

Alternately, a compound of formula (Fg) wherein one G₁ is hydrogen and the other G₁ group is benzyloxycarbonyl is treated with a 1.1 molar equivalent amount of HOBt in an inert solvent, preferably DMF, at 0°C. A 2.0 molar equivalent amount of EDCI is then added to the solution and the resulting mixture is stirred at 0°C for about 30 to 40 minutes, preferably for about 35 minutes. The solution containing the compound of formula (K) as described above is then added to the reaction mixture under similar conditions as described above to form a compound of formula (N) wherein one G₁ group is hydrogen and the other G₁ group is benzyloxycarbonyl.

The amino-protecting groups of the compounds of formula (N) are then removed by catalytic hydrogenation to form compounds of formula (O). Compounds of formula (N) wherein both G₁ groups are benzyl are deprotected by hydrogenating a solution of the compound in alcohol, preferably ethanol over 20% Pd(OH)₂/C at 50 psi hydrogen for a period of about 16 to about 30 hours, preferably for about 24 hours. The preferred conditions require the use of 0.4 to about 0.5 g of 20% Pd(OH)₂/C catalyst per gram of compound of formula (N) (Step 2 of Reaction Scheme 3).

Alternatively, compounds of formula (N) wherein one G₁ group is hydrogen and the other G₁ group is benzyloxycarbonyl are deprotected by hydrogenating a solution of the compound in alcohol, preferably ethanol, over 10% Pd/C at 50 psi hydrogen for a period of 1 to about 8 hours, preferably for about 2 hours.

A compound of formula (O) is then coupled with a compound of formula (G) under similar conditions as described above for the preparation of compounds of formula (Ia) in Reaction Scheme 2, for example, with EDCI, HOBt and DMF, to afford compounds of formula (Ia).

In summary, compounds of formulae (Ia) and (Ib), which are compounds of formula (I), are prepared by:

(1) reacting a compound of formula (J) where G₁ is an amino-protecting group selected from the group consisting of t-butoxycarbonyl, 2-(naphth-1-yloxy)ethanoyl and benzyloxycarbonyl; R¹, R³ and R⁴ are as defined above in the Summary of the Invention; with a compound of formula (K) where R¹ is as defined above in the Summary of the Invention to form a compound of formula (Ia) where G₁, R¹, R³, R⁴, and R⁷ are the same as defined above for the compound of formula (J) and the compound of formula (K); or

(2) treating a compound of formula (L) where R¹, R³, R⁴ and R⁷ are as defined above in the Summary of the Invention, with a compound of formula (M)

-25-

where R¹ is as defined above in the Summary of the Invention, to form a compound of formula (Ib) where R¹, R², R³, R⁴ and R⁷ are the same as defined above for the compound of formula (L) and the compound of formula (M); or

(3) reacting a compound of formula (O) where R⁴ and R⁷ are as defined above for the Summary of the Invention, with a compound of formula (G) where G₁ is an amino-protecting group and is selected from the group consisting of *t*-butoxycarbonyl, 2-(naphth-1-yloxy)ethanoyl and benzyloxycarbonyl; R² and R³ are as defined above in the Summary of the Invention, and R¹⁶ is hydrogen or *p*-nitrophenyl; to form a compound of formula (Ia) where G₁, R², R³, R⁴ and R⁷ are the same as defined above for the compounds of formulae (O) and (G); or

(4) oxidizing a compound of formulae (Ia) or (Ib) as described above with an oxidizing agent to form a compound of formula (I) where R⁵ and R⁶ together form oxo.

In addition, all compounds of formula (I) that exist in free base form may be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic acid. Salts of the compounds of formula (I) can also be converted to the free base form or to another salt.

The following specific preparations and examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention.

Preparation 1

Compounds of formula (Fc)

A. A solution of phenylalaninol (10 g, 0.0661 mol) and benzyl bromide (17 mL, 0.146 mol) in 200 mL potassium carbonate solution (30 g) was refluxed for four hours. The solution was cooled and extracted with ethyl acetate, the organic layer was dried over sodium sulphate and evaporated to yield *N,N*-dibenzylphenylalaninol as a crude product. The compound was recrystallized from ether/hexane (yield: 18.5 g solid), m.p. 65-67°C, MS: 331 (M⁺).

B. A solution of tyrosinol hydrochloride (9.8 g, 0.048 mol) and benzyl bromide (16.5 g, 0.096 mol) in 200 mL potassium carbonate solution (30 g) was refluxed for 8 hours. Benzyl bromide (16.5 g, 0.096 mol) was added and the mixture was refluxed for another 8 hours. The solution was cooled and extracted with ethyl acetate, the organic layer was dried over sodium sulphate and evaporated to the crude product. The material was purified by column chromatography (10% ethyl acetate:hexane to 50% ethyl acetate:hexane) to give 6.05 g of *N,N*-dibenzyl-*O*-benzyltyrosinol, m.p. 112-113°C, and 4.5 g of *N,N*-dibenzyltyrosinol, m.p. 155-156°C.

Preparation 2

Compounds of formula (Fd)

A. A solution of dry methylene chloride (100 mL) and oxalyl chloride (5.37 mL, 0.0616 mol) was placed in 500 mL 3-neck flask equipped with a drying tube, a stopper and a septum. DMS (14.21 mL (Aldrich), 0.200 mol) was added slowly at -60°C to -65°C over a period of 2 minutes. The reaction mixture was

stirred for 5 minutes and a solution of *N,N*-dibenzylphenylalaninol (18.5 g, 0.056 mol) in dry CH_2Cl_2 (100 mL) was added; stirring was continued for another 5 minutes. Triethylamine (23 mL, 0.165 mol) was added and the reaction mixture warmed up to room temperature. The mixture was poured onto ice-cold water and extracted with CH_2Cl_2 . The organic layer was evaporated to a very small volume and redissolved in ethyl acetate. The ethyl acetate solution was washed five times with water, dried over sodium sulphate and evaporated to give *N,N*-dibenzylphenylalaninal. This compound was purified by column chromatography (10% ethyl acetate:hexane); yield: 18 g, IR: 1725 cm^{-1} .

10 B. In a similar manner, but replacing *N,N*-dibenzylphenylalaninol with *N,N*-dibenzyl-*O*-benzyltyrosinol, *N,N*-dibenzyl-*O*-benzyltyrosinal was prepared, IR: 1705 cm^{-1} ; m.p. 75-76°C.

Preparation 3

15 Compounds of Formula (Fe)

A. A solution of *N,N*-dibenzylphenylalaninal (18 g, 0.055 mol) in dry CH_2Cl_2 (100 mL) was added to a suspension of ZnBr_2 (14.15 g, 0.0618 mol) in dry CH_2Cl_2 (100 mL) at -20°C (dry-ice, CCl_4) under argon. After 30 minutes, trimethylsilyl cyanide (11.5 mL, 0.084 mol) was added and the mixture was vigorously stirred at -20°C for 4.5 hours. The material was poured onto ice-cold water and extracted. The CH_2Cl_2 layer was dried over MgSO_4 and evaporated to give an oil. The aqueous phase was further extracted three times with ether, the ether extract was dried over MgSO_4 and evaporated to give an oil. This gave a total of 21 g of a crude product, 3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-phenylbutyronitrile, which could be used without further purification. The product was analyzed by analytical HPLC ($\text{CH}_3\text{CN}:\text{NH}_4\text{OAc}$ buffer, pH 7; gradient: 100% buffer to 100% CH_3CN over 10 minutes run; flow rate: 3 mL/min.) which indicated that the two diastereomers, (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-phenylbutyronitrile and (2*R*,3*S*)-3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-phenylbutyronitrile, were formed in 95:5 ratio, respectively. MS: 413 ($\text{M}^+ - \text{Me}$).

30 B. In a similar manner, but replacing *N,N*-dibenzylphenylalaninal with *N,N*-dibenzyl-*O*-benzyltyrosinal, 3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-(4'-benzyloxyphenyl)butyronitrile was prepared, as an oil.

35

Preparation 4

Compounds of Formula (Ff)

A. Hydrogen chloride gas was bubbled into a solution of 150 mL anhydrous ether and 50 mL absolute ethanol for 5 minutes at 0°C. The solution was stirred in an Aldrich cool-stir, which was maintained at 5°C, and a solution of 3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-phenylbutyronitrile (21 g, existing as a 95:5 diastereomer mixture, as described above in Preparation 3) in 30 mL ether was added. The mixture was stirred at 5°C for 24 hours. Ice-cold water (25 mL) was added dropwise. The resulting mixture was vigorously stirred at 5°C for another 48 hours. The mixture was neutralized

45

-27-

by adding it slowly to a mixture of sodium bicarbonate and ethyl acetate in a large beaker. The insoluble inorganic was suction-filtered after neutralization and the mixture was extracted with ethyl acetate. The ethyl acetate layer was dried over sodium sulphate and evaporated to give an oil which was purified by column chromatography (elution gradient: 10% ethyl acetate:hexane to 50% ethyl acetate:hexane). Overlapping fraction of the esters could be further purified by prep-HPLC (silica gel, 15% ethyl acetate:hexane). There was obtained 220 mg of (2*R*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid ethyl ester, 8.2 g of (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid ethyl ester, as an oil, MS: 402 ($M^+ - H$); IR: 3500, 1725 cm^{-1} , and 1.1 g of (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid amide, recrystallized from ethyl acetate:hexane, m.p. 118-119°C; MS: 331 (M^+); IR: 3300, 1645, 1655 cm^{-1} .

B. In a similar manner, but replacing 3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-phenylbutyronitrile with 3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-(4'-benzyloxyphenyl)butyronitrile, the following compounds were made:

(2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-(4'-benzyloxyphenyl)butanoic acid ethyl ester, oil, MS: 510 (M^+); and
(2*R*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-(4'-benzyloxyphenyl)butanoic acid ethyl ester, oil, MS: 510 (M^+).

Preparation 5

Compounds of Formula (Ff) (Step 4b)

A. A solution of (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-phenylbutyronitrile and (2*R*,3*S*)-3-*N,N*-dibenzylamino-2-trimethylsilyloxy-4-phenylbutyronitrile (2 g, 95:5 diastereomeric mixture) in dioxane (15 mL) was mixed with concentrated HCl and refluxed for 16 hours. The material was evaporated to dryness. A small amount of water was added and the pH of the solution was adjusted to pH 4 with NH_4OH . The solution was extracted with ethyl acetate, the organic layer was dried over sodium sulphate and evaporated to give an oil. Column chromatography (elution gradient: 50% ethyl acetate:hexane to ethyl acetate to 12% $\text{MeOH}:\text{CH}_2\text{Cl}_2$) gave 450 mg of 3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid, as an oil. The aqueous phase was purified by ion-exchange chromatography to give another 60 mg of the acid as a white solid, m.p. >250°C; MS: 374 ($M^+ - H$).

B. (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid (780 mg) was added to a saturated solution of hydrogen chloride in absolute ethanol. The mixture was stirred at room temperature for 24 hours. The solvent was removed in vacuo and the residue was mixed with ethyl acetate and NaHCO_3 solution. The mixture was extracted, the organic layer was dried over sodium sulphate, and evaporated to give an oil, which was purified by column chromatography (18% ethyl acetate:hexane) to give (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid ethyl ester as an oil, yield: 800 mg.

45

Preparation 6

Compounds of Formula (F) (As prepared by Reaction Scheme 1a)

5 A. Pd(OH)₂/C (1.3 g, Aldrich) was added slowly to a solution of (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid ethyl ester (2.6 g) in absolute ethanol (200 mL) in a Parr bottle under argon. The solution was hydrogenated at 50 psi H₂ for 16 hours. The solution was flushed with argon and the catalyst filtered through Celite. The filtrate was evaporated to give (2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoic acid ethyl ester as an oil, yield: 1.31 g, MS: 224 (M+H)⁺.

10 B. In a similar manner, the following compound was made: (2*S*,3*S*)-3-amino-2-hydroxy-4-(4'-hydroxyphenyl)butanoic acid ethyl ester, MS: 240 (MH)⁺.

Preparation 7

15 Compounds of Formula (E)

A. *N*-Methylpiperidine (8.20 mL, 66.8 mmol) was added to a suspension of *N*-methyl-*O*-methylhydroxyamine hydrochloride (8.14 g, 83.5 mmol) in CH₂Cl₂ (50 mL) at 0°C and the resulting mixture was stirred at 0°C for 30 minutes. Meanwhile, *N*-methylpiperidine (8.20 mL, 66.8 mmol) was added to a solution of benzyloxycarbonyl-L-phenylalanine (20 g, 66.8 mmol) in CH₂Cl₂ (50 mL) and tetrahydrofuran (50 mL) at 10°C. Methyl chloroformate (5.21 mL, 66.8 mmol) was added dropwise at -10°C to this solution, and the resulting mixture was stirred for 10 minutes. The solution of the *N*-methyl-*O*-methylhydroxyamine in CH₂Cl₂ was added and the resulting mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was partitioned between CH₂Cl₂ and water. The organic layer was washed with 0.2 N NaOH, brine, dried over Na₂SO₄ and evaporated to give crude benzyloxycarbonyl-L-phenylalanyl-*N*-methyl-*O*-methanamide. The product was further purified by column chromatography (30% ethyl acetate:hexane to 70%) to give 13.5 g of benzyloxycarbonyl-L-phenylalanyl-*N*-methyl-*O*-methanamide as an oil.

25 B. LiAlH₄ (332 mg, 8.73 mmol) was added portionwise to 25 mL of dry tetrahydrofuran at 0°C under argon. A solution of benzyloxycarbonyl-L-phenylalanyl-*N*-methyl-*O*-methanamide (3 g, 8.76 mmol) in dry tetrahydrofuran (50 mL) was added slowly at 0°C over 15 minutes, and the resulting mixture was stirred for 60 minutes at the same temperature. A mixture of ethyl acetate and tetrahydrofuran (50 mL each) was added slowly. After 15 minutes, the mixture was poured slowly into ice-cold 1N HCl (100 mL) and then extracted with ethyl acetate. The organic layer was washed with saturated NaCl, dried over Na₂SO₄ and evaporated to give an oil which was further purified by column chromatography (30% ethyl acetate: hexane) to give benzyloxycarbonyl-L-phenylalanyl-*N*-methyl-*O*-methanamide as a solid (2.11 g).

35 C. A solution of NaHSO₃ (0.773 g, 7.42 mmol) in water (5 mL) was added slowly to a solution of benzyloxycarbonyl-L-phenylalanyl-*N*-methyl-*O*-methanamide (2 g) in acetonitrile (5 mL) at 5°C and the mixture was stirred at 5°C overnight. Ethyl acetate (60 mL) and a solution of KCN (0.966 g, 14.84 mmol) in water (10

-29-

mL) were added and the resulting mixture were stirred at room temperature for 4 hours. The organic layer was washed with water, dried over Na_2SO_4 and evaporated to give the cyanohydrin as an oil (2.24 g).

5 D. A solution of the cyanohydrin (2.24 g) in dioxane (5 mL) and concentrated HCl (15 mL) was refluxed for 16 hours. The solution was cooled, adjusted to pH 7 with 2N NaOH and extracted with ether. The aqueous extract was loaded onto an ion-exchange column (Cation exchange resin AG50W-X8, 100-200 mesh hydrogen form). The material was eluted with water (500 mL), followed by 1N NH_4OH . The basic extract was evaporated to about 2 mL and
10 mixed with acetone, the insoluble solid was filtered to give 3-amino-2-hydroxy-4-phenylbutanoic acid (1.45 g).

E. Trimethylsilyl cyanide (3.07 mL, 23 mmol) was added to a suspension of 3-amino-2-hydroxy-4-phenylbutanoic acid (1 g, 5.12 mmol) in CH_3CN (20 mL) and stirred for 20 minutes. The suspension was cooled to 5°C,
15 benzyl chloroformate (0.81 mL, 5.6 mmol) was added slowly and the mixture was stirred at room temperature for 4 hours. The mixture was mixed with ice-cold water and evaporated to remove CH_3CN . The residue was extracted between ethyl acetate and water, the organic layer was dried over Na_2SO_4 and evaporated to give 3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid as a solid (1.1
20 g).

F. A mixture of benzyloxycarbonyl-L-phenylalaninal (4.1 g, 14.57 mmol) and tributyltin cyanide (5.53 g, 17.48 mmol) in dry CH_2Cl_2 (150 mL) was stirred at -40°C for 30 minutes. The mixture was evaporated to dryness, the crude cyanohydrin was dissolved in a dried and cooled mixture of
25 ether/methanol (3:1) at 0°C, previously saturated with HCl (100 mL). The solution was stirred at 5°C for 24 hours, ice-cold water (15 mL) was added dropwise, and the resulting mixture was stirred at 5° to 10°C for 48 hours. The mixture was concentrated and extracted with CH_2Cl_2 . The organic layer was washed with water and brine, dried over Na_2SO_4 and evaporated to give an oil (4
30 g). The material was purified by column chromatography (28% ethyl acetate:hexane) to give (2S,3S)-3-benzyloxy-carbonylamino-2-hydroxy-4-phenylbutanoic acid methyl ester (700 mg, m.p. 121-122°C) and (2R,3S)-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid methyl ester (2 g, m.p. 94-95°C).

35

Preparation 8

Compounds of Formula (F) (As prepared by Reaction Scheme 1b)

A. A solution of (2S,3S)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid methyl ester (1 g, 2.91 mmol) in anhydrous methanol was
40 hydrogenated over 10% Pd/C at 50 psi hydrogen for 12 hours. The catalyst was filtered through Celite and the filtrate evaporated to give an oil. The oil was dissolved in ethyl acetate and dried over sodium sulphate. Solvent evaporation gave (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester, as an oil (610 mg), MS: 208 ($\text{M}^+\text{-H}$).

45 B. In a similar manner, but replacing (2S,3S)-3-benzyloxycarbonyl-

amino-2-hydroxy-4-phenylbutanoic acid methyl ester with the appropriate compound of formula (E), the following compound was made:
(2R,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester, as an oil.

5

Preparation 9

Compounds of Formula (G)

A. 1,1'-carbonyldiimidazole (0.689 g, 4.23 mmol) was added to a solution of benzyloxycarbonyl-L-aspartic acid benzyl ester (1.513 g, 4.23 mmol) in dry THF and the resulting solution was stirred at room temperature for 3 hours. Diethylamine (0.466 mL, 98% pure, 4.23 mmol) was added and the mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, the residue taken up in ethyl acetate. The ethyl acetate solution was washed successively with 1N HCl, 0.5N NaOH, brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give benzyloxycarbonyl-L-N',N'-diethylasparagine benzyl ester as an oil (1.05 g), IR: 3320-3340, 1715, 1625 cm⁻¹; MS: 412 (M⁺). This oil could be used without further purification.

B. In a similar manner, but replacing diethylamine with ethyl amine, the following compound of formula (G) was prepared:
benzyloxycarbonyl-L-N'-ethylasparagine benzyl ester, m.p. 127-128°C; MS: 384 (M⁺).

C. Benzyloxycarbonyl-L-N',N'-diethylasparagine benzyl ester (1.05 g) was hydrolyzed in 1N NaOH (8 mL) and dioxane (8 mL) at 0°C for 30 minutes. The solution was acidified with 3N HCl and evaporated to remove dioxane. The aqueous material was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulphate and evaporated to give benzyloxycarbonyl-L-N',N'-diethyl-asparagine (650 mg) as an oil, MS: 322 (M⁺).

D. In a similar manner, but replacing benzyloxycarbonyl-L-N',N'-diethylasparagine benzyl ester with benzyloxycarbonyl-L-N'-ethylasparagine benzyl ester, the following compound of formula (G) was prepared: benzyloxycarbonyl-L-N'-ethylasparagine, m.p. 145-146°C; MS: 294 (M⁺).

E. Tert-butoxycarbonyl-L-aspartic acid β-benzyl ester (2 g, 6.19 mmol) was added to a saturated solution of ammonia gas in absolute ethanol (100 mL). The solution was stirred at room temperature for two days. Solvent evaporation gave an oil which was extracted between ether and water. The aqueous layer was acidified with 3N HCl to pH of 1 and extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over sodium sulphate and evaporated to give 1.25 g of t-butoxycarbonyl-L-N'-methilasparagine as a white solid, m.p. 164-165°C.

F. Alternatively, N-methylmorpholine (2.9 g, 28.7 mmol) was added to a solution of 1-naphthoxyacetic acid (5.06 g, 25.02 mmol) in dry THF (25 mL) at -15°C, followed by the addition of isobutyl chloroformate (3.5 g, 25.62 mmol). After 5 minutes, a solution of L-valine benzyl ester.HOTs salt (9.65 g, 25.43 mmol) in THF (30 mL) and Et₃N (2.9 g, 28.71 mmol) was added. The

-31-

mixture was stirred at -15°C for 2 hours and then at room temperature for 18 hours. The material was concentrated under reduced pressure, and extracted with ethyl acetate and water. The organic extract was washed with water, saturated NH₄Cl solution, brine, dried over sodium sulphate, and evaporated to give an oil. This material was purified by column chromatography (25% ethyl acetate:hexane) to give the 2-(naphth-1-yloxy)ethanoyl-L-valine benzyl ester (8.25 g).

G. Proceeding, a solution of 2-(naphth-1-yloxy)ethanoyl-L-valine benzyl ester (4.38 g, 11.8 mmol) from above was hydrogenated over 10% Pd/C in absolute ethanol (100 ml) at 50 psi H₂ for 1 hour. A thick precipitate was formed, the suspension was diluted with CH₂Cl₂, and suction filtered through Celite. The filtrate was concentrated to give 2-(naphth-1-yloxy)ethanoyl-L-valine as a white solid (3.3 g), m.p. 199-201°C.

Preparation 10

Compounds of formula (H)

A. A solution of (2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester (610 mg, 2.95 mmol) and benzyloxycarbonyl-L-asparagine *p*-nitrophenyl ester (1.13 g, 2.92 mmol) in dry THF was stirred under argon for 2 days. The solvent was removed under reduced pressure and the residue purified by column chromatography (10% MeOH:CH₂Cl₂) to give (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoic acid methyl ester as a white solid (513 mg), m.p. 218-219°C.

B. In a similar manner, but replacing (2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester with (2*R*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester, the following compound was made: (2*R*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoic acid methyl ester, m.p. 188-189°C.

C. In a similar manner, but replacing (2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester with (2*S*,3*S*)-3-amino-2-hydroxy-4-(4'-hydroxy)phenylbutanoic acid methyl ester, the following compound was made: (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-(4'-hydroxy)-phenylbutanoic acid ethyl ester, m.p. 190-192°C, MS: 488 (M+H)⁺.

Preparation 11

Alternate Preparation of Compounds of formula (H)

A. EDCI (0.65 g, 1.43 mmol) was added to a solution of benzyloxycarbonyl-L-N',N'-diethylasparagine (0.46 g, 1.43 mmol) and HOBt (0.193 g, 1.43 mmol) in dry DMF under argon at 0°C. The resulting solution was stirred at 0°C for 20 minutes. A solution of (2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester (0.29 g, 1.43 mmol) in dry DMF was added and the solution was stirred overnight at room temperature. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was washed successively with 1N HCl, 0.5N NaOH, and brine solution. The organic solvent phase was dried over

magnesium sulphate and evaporated to give (2*S*,3*S*)-3-(benzyloxycarbonyl-L-N',N'-diethylasparaginyl)amino-2-hydroxy-4-phenylbutanoic acid methyl ester as an oil (297 mg); IR: 3300,1720,1660,1620 cm⁻¹.

5 B. In a similar manner, the following compound of formula (H) was made:

(2*S*,3*S*)-3-(benzyloxycarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoic acid ethyl ester, m.p. 160-162°C;

C. Alternatively, in a similar manner, the following compound of formula (H) wherein G₁ is 2-(naphth-1-yloxy)ethanoyl were made:

10 (2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoic acid ethyl ester, m.p. 181-182°C; and (2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-D-valyl)amino-2-hydroxy-4-phenylbutanoic acid ethyl ester, m.p. 171-173°C.

15

Preparation 12

Compounds of formula (J)

A. Sodium hydroxide solution (1*N*, 5 mL) was added to a solution of (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoic acid methyl ester (400 mg, 0.875 mmol) in dioxane (5 mL) at 0°C and the mixture was stirred for 30 minutes. A white gummy solid appeared and the suspension was acidified to pH 7 with 3*N* HCl. The solvent was removed in vacuo and the residue was acidified to pH 1 with 3*N* HCl. The insoluble solid was filtered and washed with ethyl acetate. This gave (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoic acid as a white solid (150 mg), m.p. 213-214°C. The ethyl acetate wash was separated from the water and dried over sodium sulphate; the solvent was removed in vacuo to give another crop of the product (50 mg).

20 B. In a similar manner, but replacing (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoic acid methyl ester with (2*R*,3*S*)-3-(benzyloxy-carbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoic acid methyl ester, the following compound of formula (J) was made:

(2*R*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoic acid, m.p. 195-196°C.

35 C. In a similar manner, but replacing (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoic acid methyl ester with

(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-(4'-hydroxy)phenylbutanoic acid ethyl ester, the following compound was made: (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-(4'-hydroxy)-phenylbutanoic acid, m.p. 229-230°C, MS: 460 (M+H)⁺.

40 D. In a similar manner, the following compound was made:

(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoic acid, m.p. 180-182°C.

Preparation 13

Alternate Preparation of Compounds of formula (J)

A. Sodium hydroxide solution (1N, 5 mL) was added slowly to a solution of (2S,3S)-3-(benzyloxycarbonyl-L-N',N'-diethylasparaginy)amino-2-hydroxy-4-phenylbutanoic acid methyl ester (297 mg, 0.578 mmol) in dioxane (5 mL) at 0°C. After 30 minutes, the solution was acidified with 3N HCl and the solvent was evaporated to remove the dioxane. The aqueous material was extracted with ethyl acetate (2 x 100 mL). The combined organic phase was washed successively with brine, dried over sodium sulphate and evaporated to give (2S,3S)-3-(benzyloxycarbonyl-L-N',N'-diethylasparaginy)amino-2-hydroxy-4-phenylbutanoic acid as a clear oil (200 mg), which could be recrystallized from ether/CH₂Cl₂/hexane, m.p. 138-139°C, IR: 3320, 3340, 2500-3200(br), 1720, 1700, 1660 cm⁻¹.

B. In a similar manner, the following compound of formula (J) was prepared:
(2S,3S)-3-(benzyloxycarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoic acid, m.p. 190-192°C.

Preparation 14

Amino-protected compounds of Formula (K) and
Compounds of Formula (K)

A. Finely powdered 2-t-butyloxycarbonyloximinophenylacetonitrile (2.06 g, 8.5 mmol) was added to a stirred solution of L-pipecolic acid (1 g, 7.66 mmol) and triethylamine (1.62 mL, 11.49 mmol) in water (6 mL) and dioxane (6 mL). After about one hour the mixture became homogeneous; stirring was continued for two more hours. Water (80 mL) and ethyl acetate (120 mL) were added, the aqueous layer was separated and re-extracted with ethyl acetate. The aqueous layer was acidified with citric acid, and then extracted with ethyl acetate (3 x 80 mL). The organic phase was washed successively with water, dried over sodium sulphate and evaporated to give N-t-butyloxycarbonyl-L-pipecolic acid, 1.29 g, m.p. 122-123°C.

B. Proceeding, EDCI (2 g, 10.2 mmol) was added to a solution of N-t-butyloxy-carbonyl-L-pipecolic acid (1.17 g, 5.1 mmol) and HOBT (0.69 g, 5.1 mmol) in dry DMF under argon at 0°C. The resulting solution was stirred at 0°C for 20 minutes. A solution of t-butylamine (0.54 mL, 5.1 mmol) in dry DMF (2 mL) was added and the resulting solution was stirred overnight at room temperature. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was washed successively with 1N HCl, 0.5N NaOH, and brine solution. The organic solvent phase was dried over magnesium sulphate and evaporated to give a crude product as a brown oil. This oil was purified by column chromatography (40% ethyl acetate:hexane) to give pure (2S)-N-t-butyloxycarbonylpiperidine-2-N'-t-butyl-carboxamide (1.05 g) m.p. 132-133°C; IR. 3310, 1660 cm⁻¹.

C. In a similar manner as above, the following compounds were made:
N-t-butoxycarbonyl-N'-t-butyl-L-prolinamide, m.p. 192-193°C;

- N*-*t*-butoxycarbonyl-*N'*-*t*-butyl-D-prolinamide, m.p. 123-124°C;
N-*t*-butoxycarbonyl-*N'*-(1-hydroxy-2-methylpropyl-2-yl)-L-prolinamide,
m.p. 192-193°C;
N-*t*-butoxycarbonyl-*N'*-(pyrid-2'-ylmethyl)-L-prolinamide, m.p. 123-124°C;
5 *N*-*t*-butoxycarbonyl-*N'*-(2-(pyrid-2'-yl)ethyl)-L-prolinamide, m.p. 124-126°C;
N-*t*-butoxycarbonyl-*N'*-cyclohexyl-L-prolinamide, m.p. 142-143°C;
N-*t*-butoxycarbonyl-*N'*-(2-(morpholin-4-yl)ethyl)-L-prolinamide,
m.p. 127-128°C;
N-*t*-butoxycarbonyl-*N'*-*t*-butyl-L-phenylalaninamide, m.p. 131-133°C;
10 *N*-*t*-butoxycarbonyl-*N'*-*t*-butyl-L-cyclohexylalaninamide, m.p. 164-165°C;
N-benzyloxycarbonyl-*N'*-*t*-butyl-(4*R*)-hydroxy-L-prolinamide, m.p. 124-125°C;
(2*S*,3*aS*,7*aS*)-1-*t*-butoxycarbonyloctahydroindole-2-*N'*-(1-benzylpiperidin-4-yl),
as a white foam;
(2*S*,3*aS*,7*aS*)-1-*t*-butoxycarbonyloctahydroindole-2-*N'*-iso-propylcarboxamide,
15 m.p. 136-137°C;
(4*S*)-3-butoxycarbonylthiazolidine-4-*N'*-*t*-butylcarboxamide,
m.p. 131-133°C; and
N-benzyloxycarbonyl-*N'*-*t*-butyl-(4*S*)-hydroxy-L-prolinamide, m.p. 129-130°C.

D. In a similar manner as above, *N*-benzyloxycarbonyl-1,2,3,4-tetra-
20 hydroisoquinoline-3-carboxylic acid (2.41 g) was converted to *N*-benzyloxy-
carbonyl-1,2,3,4-tetrahydroisoquinoline-3-*N'*-*t*-butylcarboxamide. The material
was used without further purification. A solution of the amide in absolute
ethanol was hydrogenated over 10% Pd/C at 50 psi H₂ for 16 hours. The
catalyst was filtered through Celite and the filtrate evaporated to give
25 1,2,3,4-tetrahydroisoquinoline-3-*N'*-*t*-butylcarboxamide (580 mg). This
material was redissolved in absolute ethanol and hydrogenated over 5%
Rh/alumina for 3 hours at 60 psi H₂. The catalyst was filtered through Celite
under suction, and the filtrate evaporated to give (3*RS*,4*aRS*,8*aRS*)-
decahydroisoquinoline-3-*N'*-*t*-butylcarboxamide (415 mg), IR: 3300,1655 cm⁻¹.

30 E. Alternatively, (3*S*,4*aS*,8*aS*)-decahydroisoquinoline-3-*N'*-*t*-
butylcarboxamide can be prepared according to the procedure described in
European Published Patent Application 0 432 695 (J.A. Martin and S. Redshaw).

F. Octahydro-1*H*-isoindole-1-carboxylic acid hydrochloride was
prepared according to the procedures described in the following references:
35 G. Gignarella, R. Cerri, G. Grella, P. Sanna; *Gazzetta Chimica Italiana*
(1976), Vol. 106, pp. 65-75; C.J. Blankley, J.S. Kaltenbronn, D.E. DeJohn, A.
Werner, L.R. Bennett, G. Bobowski, U. Kroll, D.R. Johnson, W.M. Pearlman,
M.L. Hoefle, A.D. Essenburg, D.M. Cohen and H.R. Kaplan, *J. Med. Chem.* (1987),
Vol. 30, pp. 992-998. Octahydroindole-(2*S*)-carboxylic acid can be obtained
40 commercially from Kawaken Fine Chemicals Co. Ltd, Japan. Proceeding in a
similar manner as described above, octahydro-1*H*-isoindole-1-carboxylic acid
hydrochloride and (2*S*,3*aS*,7*aS*)-octahydroindole-2-carboxylic acid were
converted into the following compounds:
1-*N'*-*t*-butylcarbonyl-2-*t*-butoxycarbonyloctahydro-1*H*-isoindole;
45 IR: 1660-1680, 3320 cm⁻¹;

(2*S*,3*aS*,7*aS*)-2-*N'*-*t*-butylcarbamoyl-1-*t*-butoxycarbonyloctahydroindole,
m.p. 116-117°C; and
(2*S*,3*aS*,7*aS*)-2-*N'*-*iso*-propylcarbamoyl-1-*t*-butoxycarbonyloctahydroindole,
m.p. 139-140°C.

5 G. Alternatively, a mixture of formic acid (42 μ L, 1.1 mmol) and triethylamine (0.15 mL, 1.1 mmol) in toluene (5 mL) was added to a solution of triphenylphosphine (289 mg, 1.1 mmol) and (4*R*)-hydroxy-*N'*-*t*-butyl-L-prolinamide (321 mg, 1 mmol) in toluene (20 mL) and DMF (5 mL) at room temperature. A solution of diethyl azidodicarboxylene (DEAD) (0.10 mL,
10 1.1 mmol) in toluene (5 mL) was then added and the mixture was stirred for 1 day at room temperature. The solvent was removed under reduced pressure and the residue partitioned between ethyl acetate and water. The organic extract was dried over sodium sulphate and evaporated to give an oil which was purified by column chromatography (40% ethyl acetate:hexane) to give (4*S*)-*N*-benzyloxycarbonyl-4-formyl-*N'*-*t*-butyl-L-prolinamide, 260 mg;
15 IR: 1712, 1690 cm^{-1} .

H. Proceeding, a solution of (4*S*)-*N*-benzyloxycarbonyl-4-formyl-*N'*-*t*-butyl-L-prolinamide (206 mg, 0.591 mmol) in methanol (3 mL) and dioxan (15 mL) was mixed with 1*N* NaOH (3 mL) and stirred at 0°C for 10 minutes. The solution
20 was neutralized to pH of 7 with 3*N* HCl and then evaporated to remove all organic solvent. The aqueous material was extracted with ethyl acetate, and the organic layer further washed with saturated NaHCO₃ solution and brine. The organic layer was dried over sodium sulphate and evaporated to give (4*S*)-hydroxy-*N*-benzyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide, 157 mg, m.p. 129-130°C.

25 I. Proceeding, a solution of *t*-butyl isocyanate (0.09 mL, 0.77 mmol) and (4*S*)-hydroxy-*N*-benzyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide (200 mg, 0.622 mmol) in toluene was refluxed for 3 days. The solvent was evaporated to dryness and the residue partitioned between ethyl acetate and water. The organic layer was dried over sodium sulphate and evaporated to give an oil
30 which was purified by column chromatography (40% ethyl acetate:hexane) to give (4*R*)-(N'-*t*-butyl)carbamoyloxy-*N*-benzyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide, 100 mg. H-NMR (80 MHz): 1.26 (m,18H,2*t*-Bu), 2.2-2.4 (m,2H,CH₂), 3.6-3.7 (m,2H,CH₂), 4.3 (m,1H,CH), 5.16 (s,2H,CH₂), 7.33 (s,5H,Ph).

J. Proceeding in a similar manner as described above, (4*S*)-hydroxy-*N*-benzyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide was converted to (4*R*)-(N'-*t*-butyl)carbamoyloxy-*N*-benzyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide; H-NMR (80
35 MHz): 1.30 (2s,18H,2*t*-Bu), 2.2-2.4 (m,2H,CH₂), 3.6-3.7 (m,2H,CH₂), 4.3 (m,1H,CH), 5.20 (s,2H,CH₂), 7.35 (s,5H,Ph).

K. Alternatively, Sodium hydride (542 mg, 50% oil, 11.3 mmol) was added slowly to a solution of (4*R*)-ethoxy-*N*-benzyloxycarbonyl-L-proline (1.5
40 gm, 5.65 mmol) in dry THF (100 mL). The solution was stirred at room temperature for 45 minutes. Ethyl iodide (1.78 g, 11.3 mmol) was added and the mixture was refluxed for 3 hours and then stirred at room temperature for 18 hrs. The solvent was evaporated to dryness and the residue partitioned
45 between ethyl acetate and water. The aqueous layer was acidified to pH of 1

with 3N HCl and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulphate and evaporated to give 1 g. (4R)-ethoxy-N-benzyloxycarbonyl-L-proline, as an oil. Without further purification, a solution of (4R)-ethoxy-N-benzyloxycarbonyl-L-proline (500 mg, 1.7 mmol) and HOBt (261 mg, 1.7 mmol) in dry DMF (20 mL) was mixed with EDCI (811 mg, 4.25 mmol) and stirred at 0°C for 60 minutes. *tert*-butylamine (0.19 mL, 1.7 mmol) was added and the mixture was stirred overnight. The solvent was removed under reduced pressure, and the residue partitioned between ethyl acetate and water. The organic layer was washed with saturated NaHCO₃ solution, brine, dried over sodium sulphate and evaporated to give an oil. The oil was purified by column chromatography (40% ethyl acetate:hexane) to give 244 mg of (4R)-ethoxy-N-benzyloxycarbonyl-N'-*t*-butyl-L-prolinamide; MS: 318 (M⁺).

L. Proceeding, a solution of (4R)-ethoxy-N-benzyloxycarbonyl-N'-*t*-butyl-L-prolinamide (200 mg) in dry ethanol (50 mL) was hydrogenated over 10% Pd/C at 50 psi H₂ for 2 hours. The solution was suction filtered through Celite and the filtrate was evaporated to give an oil which was purified by column chromatography (10% MeOH:CH₂Cl₂) to give (4R)-ethoxy-N'-*t*-butyl-L-prolinamide (70 mg) as an oil; MS: 215 (M+H)⁺.

M. Alternatively, *N*-methylmorpholine (1.3 g, 12.9 mmol) was added to a solution of *N*-*t*-butoxycarbonyl-L-proline (2.1 g, 9.77 mmol) in dry THF (25 mL) at -15°C, followed by the addition of isobutyl chloroformate (1.34 g, 9.77 mmol). After 5 minutes, a solution of 2-aminopyridine (0.91 g, 9.7 mmol) in THF was added. The mixture was stirred at -15°C for 2 hours and then at room temperature for 18 hours. The material was concentrated under reduced pressure, and then extracted with ethyl acetate and water. The organic extract was washed with water, saturated NH₄Cl solution, brine, dried over sodium sulphate, and evaporated to give an oil. This material was purified by column chromatography (40% ethyl acetate:hexane) to give (2S)-*N*-*t*-butoxycarbonyl-N'-pyrid-2-yl-L-prolinamide (380 mg).

N. Proceeding, (2S)-*N*-*t*-butoxycarbonyl-N'-pyrid-2-yl-L-prolinamide (262 mg, 0.9 mmol) was mixed with a solution of CH₂Cl₂ (70 mL), presaturated with HCl gas, for 2 hours in an ice bath. The solvent was evaporated to dryness and the residue mixed with ethyl acetate (60 mL) and Et₃N (10 mL). The suspension was filtered and the filtrate evaporated to give (2S)-N'-pyrid-2-yl-L-prolinamide as an oil (164 mg).

O. Alternatively, a racemic mixture of (1S,3S,5S)-endo-2-azabicyclo[3.3.0]octane-3-carboxylic acid and (1R,3R,5R)-endo-2-azabicyclo[3.3.0]octane-3-carboxylic acid was prepared according to the procedure of V. Teetz, R. Geiger, H. Gaul, *Tetrahedron Letters* (1984), p. 4479. A solution of the racemic mixture (1.1 gm, 6.3 mmol) in dioxane (3 mL), water (3 mL) and Et₃N (1.3 mL, 9.5 mmol) was added 2-*t*-butoxycarbonyloximino-2-phenylacetonitrile (1.57 g, 6.3 mmol). The mixture was stirred at room temperature for 2 hours, and then extracted with ethyl

acetate. The aqueous extract was acidified with citric acid and extracted with ethyl acetate. The ethyl acetate extract was washed with brine, dried over sodium sulphate and evaporated to give a racemic mixture of (1*S*,3*S*,5*S*)-2-(*t*-butoxycarbonyl)-endo-2-azabicyclo[3.3.0]octane-3-carboxylic acid and (1*R*,3*R*,5*R*)-2-(*t*-butoxycarbonyl)-endo-2-azabicyclo[3.3.0]octane-3-carboxylic acid, as an oil (1.26 g), MS: 255 (MH)⁺.

P. Proceeding, *t*-butylamine (0.25 mL, 2.3 mmol) was coupled with the racemic mixture formed in Paragraph O above (589 mg, 2.3 mmol) using the EDCI (440 mg, 2.3 mmol) and HOBT (353 mg, 2.3 mmol) procedure cited above in Paragraph B. The product was purified by column chromatography (30% ethyl acetate:hexane to 100% ethyl acetate) to give a racemic mixture of (1*S*,3*S*,5*S*)-2-(*t*-butoxycarbonyl)-endo-2-azabicyclo[3.3.0]octane-3-*t*-butylcarboxamide and (1*R*,3*R*,5*R*)-2-(*t*-butoxycarbonyl)-endo-2-azabicyclo[3.3.0]octane-3-*t*-butylcarboxamide (530 mg), m.p. 129-130°C.

Q. Alternatively, LDA (1.5 M THF solution from Aldrich, 13.9 mL, 20.8 mmol) was added to a solution of (1*S*,3*aS*,7*aR*)-2-*t*-butoxycarbonyloctahydroisindole-1-*N'*-*t*-butylcarboxamide and (1*R*,3*aR*,7*aS*)-2-*t*-butoxycarbonyloctahydroisindole-1-*N'*-*t*-butylcarboxamide (1 g, 5.4 mmol) in dry THF at 0°C and the mixture was stirred for 1 hour. The reaction was quenched with acetic acid and the mixture partitioned between ethyl acetate and 1.5 N HCl. The organic phase was dried over sodium sulphate and evaporated to give an oil. This oil was recrystallized from 20% ethyl acetate:hexane to give a solid. Without purification, this solid was added to 20% HCl solution and refluxed for 24 hours. The material was concentrated to give an oil which was pumped overnight. The oil was mixed with THF (20 mL) and Et₃N (3 mL). Di-*t*-butyl pyrocarbonate (2.4 g, 11 mmol) was added to the mixture and the resulting mixture was stirred for 8 hours. The material was evaporated to dryness and partitioned between 1N HCl and ethyl acetate. The organic phase was dried over sodium sulphate and evaporated to give an oil. This oil was mixed with EDCI (1.5 g, 8.1 mmol), *t*-butylamine (0.85 mL, 8.1 mmol), 4-dimethylaminopyridine (100 mg, 0.81 mmol) in CH₂Cl₂ at 0°C. After stirring at room temperature for 16 hours, the mixture was washed with water and 1N HCl. The organic phase was dried over sodium sulphate and evaporated to give a diastereomeric mixture of 2-*t*-butoxycarbonyloctahydroisindole-1-*N'*-*t*-butylcarboxamide. The mixture was separated on HPLC (25% ethyl acetate:hexane, silica gel) to give a less polar component, which was the recovered starting material (600 mg). The polar component was the racemic mixture of (1*R*,3*aS*,7*aR*)-octahydroisindole-1-*N'*-*t*-butylcarboxamide and (1*S*,3*aR*,7*aS*)-octahydroisindole-1-*N'*-*t*-butylcarboxamide (150 mg). Without purification, this racemic mixture (150 mg) was treated with 15% CF₃COOH in CH₂Cl₂ for 16 hours. The solvent was evaporated to give an oil which was mixed with Et₃N (0.3 mL) and CH₂Cl₂ (10 mL). After 30 minutes, the material was evaporated to dryness and purified by column chromatography (10% MeOH:CH₂Cl₂) to give 104 mg of a white foam, which was (1*R*,3*aS*,7*aR*)-octahydroisindole-1-*N'*-*t*-butylcarboxamide and (1*S*,3*aR*,7*aS*)-octahydroisindole-1-*N'*-*t*-butylcarboxamide.

R. Alternatively, *t*-butylchloroacetate (1.73 g, 15.2 mmol) was added to a solution of *N*-benzyloxycarbonyl-(*L*)-pyroglutamic acid (2 g, 7.6 mmol) in CH_2Cl_2 (25 mL) and cyclohexane (25 mL), followed by $\text{BF}_3\cdot\text{Et}_2\text{O}$ (0.2 mL). The mixture was stirred overnight and the insoluble material filtered. The filtrate was washed with NaHCO_3 solution, dried over sodium sulphate and evaporated to give an oil. This oil was purified by column chromatography (50% ethyl acetate:hexane) to give *N*-benzyloxycarbonyl-*L*-pyroglutamic acid *t*-butyl ester (1.26 g). Ethylmagnesium bromide solution (1.9 mL, 1M solution in THF, Aldrich) was added to a solution of *N*-benzyloxycarbonyl-*L*-pyroglutamic acid *t*-butyl ester (1.23 g, 3.7 mmol) in dry THF (20 mL) at -40°C . The mixture was stirred at that temperature for 2 hours at which time the reaction was quenched with dropwise addition of 3N HCl. The solution was extracted with ethyl acetate. The organic layer was dried over sodium sulphate and evaporated to give an oil. Column chromatography (silica gel, 20% ethyl acetate:hexane) gave (2*S*)-2-benzyloxycarbonylamino-5-oxoheptanoic acid *t*-butyl ester, as an oil (356 mg), IR:3350, 1730, 1710, 1690 cm^{-1} .

S. Proceeding, a solution of *tert*-butyl 2(*S*)-carbobenzyloxyamino-5-oxo-heptanoate (300 mg) in absolute ethanol was hydrogenated over 10% Pd/C at 50 psi. H_2 for 16 hours. The catalyst was suction filtered through Celite, the filtrate evaporated to give an oil. The oil was chromatographed (50% ethyl acetate:hexane to ethyl acetate) to give 5(*S*)-ethyl-*L*-proline *t*-butyl ester (120 mg), as an oil.

T. Alternatively, diethyl 3-phenylpyrrolidine-2,2-dicarboxylate can be prepared according to the procedure of Cox D.A., et al., *J. Chem. Soc.* (1964), p. 5024. To a solution of diethyl 3-phenylpyrrolidine-2,2-dicarboxylate was dissolved in 4N NaOH and stirred at room temperature for 16 hours, 10 mL of concentrated HCl was added and the mixture was refluxed for 6 hours. The solution was cooled and KOH pellet was added to bring the pH to 12. The solution was chilled to 0°C and a solution of benzyloxycarbonyl chloride in 15 mL dioxane was added. The solution was stirred for 20 hours at room temperature and then extracted with ether. The aqueous layer was acidified to pH 2 with HCl and extracted four times with ethyl acetate. The organic layer was washed with brine, dried over sodium sulphate and evaporated to give 1-benzyloxycarbonyl-3-phenylproline as a solid, which was recrystallized from ethyl acetate:hexane (1.2 g), m.p. $165-166^\circ\text{C}$, MS:324 ($\text{M}-\text{H}$) $^+$.

U. Proceeding, a solution of 1-benzyloxycarbonyl-3-phenylproline in dry DMF (1.01 g, 3.07 mmol) was mixed with EDCI (1.46 g, 7.6 mmol) and HOBt (470 mg, 3.07 mmol) at 0°C . After 1 hour, a solution of *t*-butylamine (0.40 mL, 0.24 mmol) in dry DMF (4 mL) was added. After stirring for 16 hours, the solution was evaporated to dryness under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic extract was washed with saturated sodium bicarbonate solution, brine, dried over sodium sulphate and evaporated to give an oil. The material was purified by column chromatography (30% ethyl acetate:hexane) to give two diastereomers. The less polar diastereomer was assigned the racemic mixture of *cis*-1-benzyloxy-

carbonyl-3-phenyl-N'-t-butyl-D,L-prolinamide (160 mg, oil, m.p. 143-144°C) and the more polar diastereomer was assigned the racemic mixture of *trans*-1-benzyloxycarbonyl-3-phenyl-N'-t-butyl-D,L-prolinamide (480 mg, solid), m.p. 144-145°C.

5 V. Proceeding, a solution of *trans*-1-benzyloxycarbonyl-3-phenyl-N'-t-butyl-D,L-prolinamide (440 mg, 1.15 mmol) in absolute ethanol was hydrogenated over 10% Pd/C at 50 psi H₂ for 2 hours. The catalyst was filtered through Celite and the residue was evaporated to give a solid. The material was purified by column chromatography to give 244 mg of *trans*-3-phenyl-N'-t-butyl-D,L-prolinamide as a yellow solid, m.p. 110-111°C.

10 W. Proceeding in a similar manner, *cis*-3-phenyl-N'-t-butyl-D,L-prolinamide was obtained as an oil.

X. Proceeding in a similar manner as described above in Paragraphs T, U and V, diastereomers of 3-ethyl-N'-t-butylprolinamide were prepared.

15

Preparation 15

Compounds of formula (L)

A. A solution of 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyloxy)-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide (191 mg, 0.414 mmol) in absolute ethanol was hydrogenated at 50 to 60 psi H₂ over 10% Pd/C for 6 hours. The catalyst was filtered through Celite, and the filtrate evaporated to give 1-[(2*S*,3*S*)-3-L-asparaginyloxy-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide as a foamy solid (138 mg, recrystallized from CH₂Cl₂/ether, m.p. 92-93°C). MS: 462.2 (M⁺), 171.

25 B. In a similar manner, but replacing 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyloxy)-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide with the appropriate compound of formula (Ia), the following compounds of formula (L) were made:

1-[(2*S*,3*S*)-3-L-N',N'-diethylasparaginyloxy-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, 133 mg; as an oil;

(2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-L-asparaginyloxy-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-N'-t-butylcarboxamide, 160 mg, m.p. 104-105°C;

1-[(2*S*,3*S*)-3-L-valylamino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, oil; and

35 (2*S*)-1-[(2*S*,3*S*)-3-L-asparaginyloxy-2-hydroxy-4-phenylbutanoyl]piperidine-2-N'-t-butylcarboxamide.

C. In a similar manner, the following compounds were made:

(2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-((2*S*)-ethylglycylamino-2-hydroxy-4-phenylbutanoyl)octahydroindole-2-N'-t-butylcarboxamide, as a white solid;

40 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-L-valylamino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-N'-t-butylcarboxamide, m.p. 148-149°C;

1:1 mixture of (1*S*,3*aR*,7*aS*)-1-[(2*S*,3*S*)-3-L-asparaginyloxy-2-hydroxy-4-phenylbutanoyl]octahydroisindole-1-N'-t-butylcarboxamide and (1*R*,3*aS*,7*aR*)-1-[(2*S*,3*S*)-3-L-asparaginyloxy-2-hydroxy-

- 4-phenylbutanoyl]octahydroisindole-1-*N'*-*t*-butylcarboxamide;
 1:1 mixture of (1*S*,3*aS*,7*aR*)-1-[(2*S*,3*S*)-3-*L*-asparaginylamino-2-hydroxy-
 4-phenylbutanoyl]octahydroisindole-1-*N'*-*t*-butylcarboxamide and
 (1*R*,3*aR*,7*aS*)-1-[(2*S*,3*S*)-3-*L*-asparaginylamino-2-hydroxy-
 5 4-phenylbutanoyl]octahydroisindole-1-*N'*-*t*-butylcarboxamide;
 1:1 mixture of (1*S*,3*S*,5*S*)-1-[(2*S*,3*S*)-3-(*L*-asparaginyl)amino-2-hydroxy-
 4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-*N'*-*t*-butylcarboxamide
 and (1*R*,3*R*,5*R*)-1-[(2*S*,3*S*)-3-(*L*-asparaginyl)amino-2-hydroxy-
 4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-*N'*-*t*-butylcarboxamide; and
 10 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-*L*-asparaginylamino-2-hydroxy-4-(4'-hydroxy)-
 phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 85-86°C.

Preparation 16

Compounds of Formula (M)

- 15 A. Ethyl bromoacetate (1.68 mL, 15.15 mmol) was added to a suspension
 of 6-bromo-2-naphthol (3.5 g, 97% pure, 15.21 mmol) and potassium carbonate
 (2.7 g, 19.56 mmol) in dry DMF (40 mL), followed by tetra-*N*-butylammonium
 iodide (100 mg). The mixture was stirred for 16 hours and filtered. The
 filtrate was evaporated to give an oil which was then extracted with ethyl
 20 acetate and water. The organic layer was dried over magnesium sulphate,
 evaporated to give a solid which was recrystallized from CH₂Cl₂/hexane. This
 gave ethyl 6'-bromo-2'-naphthoxyacetate as a white solid, 3.72 g; m.p. 86-
 87°C; MS: 308 (M⁺).

- B. In a similar manner, the following compounds were made:
 25 ethyl 1'-bromo-2'-naphthoxyacetate, m.p. 73-74°C;
 ethyl 3-hydroxymethyl-phenoxy acetate;
 ethyl quinolin-8'-yloxyacetate, oil; and
 ethyl quinolin-4'-yloxyacetate, m.p. 159-160°C.

- C. Proceeding, NaOH (1*N*, 20 mL) was added to a solution of ethyl 6'-
 30 bromo-2'-naphthoxyacetate (3.3 g) in DME (30 mL), and the solution was stirred
 for 60 minutes. The mixture was acidified to pH of 1 with 3*N* HCl, and the
 organic solvent was then removed under reduced pressure. The insoluble solid
 was extracted with acetone/water (4:1) and the insoluble material filtered.
 The filtrate was evaporated to give 6'-bromo-2'-naphthoxyacetic acid as a
 35 solid (2.8 g); m.p. 230-232°C.

- D. In a similar manner, the following compounds were made:
 1'-bromo-2'-naphthoxyacetic acid, m.p. 163-164°C;
 quinolin-8'-yloxyacetic acid, MS: 203 (M⁺); and
 quinolin-4'-yloxyacetic acid, m.p. 179-180°C.

- 40 E. Alternatively, ethyl 2-pyridoxyacetate was prepared according to
 the procedures of J. Maas, et al., *Recueil des travaux Chimiques des pays-bas*
 (1955), Vol. 74, pp. 175-178. NaOH solution (150 mg NaOH, 6.26 mmol in 7 mL
 water) was added to a solution of ethyl 2-pyridoxyacetate (0.5 g, 2.76 mmol)
 in dioxane. The material was left stirring at 0°C for 18 hours and room
 45 temperature for 30 minutes. The solution was acidified with concentrated HCl

to pH 5 and then concentrated under reduced pressure. The residue was azeotroped with CH_3CN several times to remove water. A yellow residue was formed which was mixed with CH_3CN (4 ml) and filtered. This gave 220 mg of 2-pyridoxyacetic acid as a yellow solid. M.p. 111-113°C.

5 F. Alternatively, 4-pyridoxyacetic acid was prepared according to the procedures of H.J. Den, et al., *Chem. Pharm. Bull.*, Vol. 23, No. 11, pp. 3008-3010.

10 G. Alternatively, mesyl chloride (0.44 ml, 5.68 mmol) was added to a solution of ethyl 3-hydroxymethylphenoxy acetate (1.1 g, 5.23 mmol) and Et_3N (0.9 mL, 6.5 mmol) in CH_2Cl_2 (25 ml) at 0°C. After 2 hours, a solution of imidazole (0.44 g, 6.5 mmol) and Et_3N (0.9 mL, 6.5 mmol) in DMF (3 mL) was added and the mixture was stirred overnight at room temperature. The material was concentrated and then partitioned between ethyl acetate and water. The organic phase was dried over sodium sulphate and evaporated to give crude
15 ethyl 3-(imidazolymethyl)phenoxyacetate. This material was mixed with 1N NaOH (30 mL) and MeOH (30 mL) and stirred at room temperature for 4 hours. MeOH was removed under reduced pressure and the aqueous material was extracted with ether (50 mL). The aqueous layer was acidified to pH 2 with 6N HCl and again washed with ether (50 mL). This acidic solution was applied onto BioRad
20 AG50W-X8 100-200 Mesh cation exchange resin (2 x 12 cm) and eluted with water. The product was eluted with 20% pyridine/water (300 ml). Solvent evaporation gave 3-(imidazolymethyl)phenoxyacetic acid as a semi-solid which was dried to constant weight (0.5 g). M.p. 69-70°C.

H. In a similar manner, the following compounds were made:
25 3-(morpholin-4-ylmethyl)phenoxyacetic acid, gum; and
3-([4-methylpiperazin-1-yl]methyl)phenoxyacetic acid, m.p. 188-189°C (decomp.).

Preparation 17

30 Compounds of Formula (N)

A. *N*-*t*-butyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide (2.23 g, 8.25 mol) was added to a saturated solution of HCl gas in CH_2Cl_2 (100 mL) and the resulting solution was stirred at room temperature for 1 hour. The solvent was removed *in vacuo*; the residue pumped under high vacuum for 30 minutes.
35 This material was redissolved in CH_2Cl_2 (30 mL) and neutralized with triethylamine (1.15 mL, 8.25 mmol).

B. A solution of (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoic acid (3.1 g, 8.25 mmol) and HOBt (1.26 g, 8.25 mmol) in dry DMF (20 mL) was cooled to 0°C. EDCI (3.15 g, 8.25 mmol) was added and the
40 solution was stirred at 0°C for 50 min. The solution from paragraph A above was added and the resulting mixture was stirred at room temperature for 24 hours. The solvent was removed *in vacuo* and the residue extracted with ethyl acetate and water. The organic layer was washed successively with 1N HCl, brine and dried over sodium sulphate. Solvent evaporation gave a solid which
45 was purified by column chromatography (40% ethyl acetate:hexane). The

material was recrystallized from ether:hexane to give 2.1 g of (2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoyl-*N'*-*t*-butyl-L-prolinamide as a white solid, m.p. 130-131°C.

C. Alternatively, compounds of formula (N) wherein one G₁ group is hydrogen were prepared as follows:

N-*t*-butyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide (820 mg, 3.03 mmol) was added to a saturated solution of HCl gas in CH₂Cl₂ (50 mL) and the resulting solution was stirred at room temperature for 1 hour. The solvent was removed *in vacuo* and the residue pumped under high vacuum for 30 minutes. This material was redissolved in CH₂Cl₂ and neutralized with triethylamine (0.1 mL). A solution of (2*RS*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid (1 g, 3.04 mmol) and HOBt (580 mg, 3.28 mmol) in dry DMF was cooled to 0°C. EDCI (1.45 g, 7.59 mmol) was added and the solution was stirred at 0°C for 35 minutes. The solution containing *N*-*t*-butyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide was added and the mixture was stirred at room temperature for 24 hours. The solvent was removed *in vacuo* and the residue extracted with ethyl acetate and water. The organic layer was washed with 1*N* HCl, brine and dried over sodium sulphate. Solvent evaporation gave a solid which was purified by column chromatography (60% ethyl acetate:hexane) to give 1-[(2*R*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide (less polar isomer, 438 mg) and 1-[(2*S*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide (more polar isomer, 320 mg); MS: 482.2(M+H)⁺.

25

Preparation 18

Compounds of Formula (O)

A. Pd(OH)₂/C (200 mg, Aldrich) was added slowly to a solution of the 1-(2*S*,3*S*)-3-*N,N*-dibenzylamino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide (800 mg) in absolute ethanol (100 mL) in a Parr bottle under argon. The solution was hydrogenated at 50 psi H₂ for 16 hrs. The solution was flushed with argon and the catalyst filtered through Celite. The filtrate was evaporated to give an oil which was further purified by column chromatography (elution gradient: ethyl acetate to 10% MeOH:CH₂Cl₂ to 20% MeOH:CH₂Cl₂) to yield 281 mg of 1-[(2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide, m.p. 144-145°C.

B. Alternatively, certain compounds of formula (O) may be prepared as follows: (2*S*,3*aS*,7*aS*)-octahydroindole-2-*N'*-*t*-butylcarboxamide (0.83 g, 3.7 mmol) was coupled to (2*S*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid (1.15 g, 3.49 mmol) using the procedure shown in Example 4D below. The product was recrystallized from CH₃CN to give (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide (1.44 g), m.p. 91-93°C. A solution of (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide (1.31 g, 2.45 mmol) in absolute ethanol (100 mL) was hydrogenated over 10% Pd/C (178 mg) at 50 psi H₂ for 5 hours. The catalyst

was removed by suction filtration through Celite. Solvent evaporation gave an oil which was purified by column chromatography (1% Et₃N:10% MeOH:CH₂Cl₂) to give 850 mg of (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 75-77°C.

5

Example 1

Compounds of formula (Ia) (As prepared by Reaction Scheme 2)

A. *Tert*-butyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide (135 mg, 0.496 mmol) was added to a saturated solution of HCl gas in CH₂Cl₂, and the resulting solution was stirred at room temperature for 1 hour. The solvent was removed *in vacuo*; the residue pumped under high vacuum for 30 minutes. The residue was re-dissolved in CH₂Cl₂, and neutralized with Et₃N (0.1 mL) to afford a solution of *N'*-*t*-butyl-prolinamide. A solution of (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoic acid (220 mg, 0.496 mmol) and HOBt (67 mg, 0.496 mmol) in dry DMF was cooled to 0°C. EDCI (237 mg, 1.24 mmol) was added and the solution was stirred at 0°C for 20 minutes. The solution of *N'*-*t*-butyl-L-prolinamide prepared above was added and the mixture was stirred at room temperature for 24 hours. The solvent was removed *in vacuo* and the residue extracted with ethyl acetate and water. The organic layer was washed successively with 1N HCl, brine and dried over sodium sulphate. Solvent evaporation gave a solid which was purified by column chromatography (10% MeOH:CH₂Cl₂) and thick layer plate chromatography (10% MeOH:CH₂Cl₂) to give 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide as a solid (191 mg; m.p. 116-118°C), MS: 596.3(M⁺).

B. Proceeding in a similar manner, but replacing (2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoic acid with the appropriate compound of formula (J), the following compounds of formula (Ia) were made:

30 1-[(2*R*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide; m.p. 192-193°C; MS: 595(M⁺), 495,496,398; and
1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-*N'*,*N'*-diethylasparaginy)l-amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide, m.p. 90-94°C, MS: 651 (M⁺).

C. In a similar manner, but replacing *t*-butyloxycarbonyl-*N'*-*t*-butyl-L-prolinamide with the appropriate precursor of a compound of formula (K), e.g., (2*S*,3*aS*,7*aS*)-*N*-(*t*-butyloxycarbonyl)octahydroindole-2-*N'*-*t*-butylcarboxamide, the following compounds of formula (Ia) were made:
40 (2*S*)-1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoyl]piperidine-2-*N'*-*t*-butylcarboxamide, m.p. 87-89°C;
(2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)l-amino-2-hydroxy-4-phenylbutanoyl]octahydroindol-2-*N'*-*t*-butylcarboxamide, m.p. 108-110°C;

- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-N'-(1-hydroxy-2-methylprop-2-yl)-L-prolinamide, m.p. 138-140°C;
- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-2-(1,2,3,4-tetrahydroisoquinoline)-3-carboxylic acid t-butyl ester, m.p. 103-104°C;
- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-D-prolinamide, m.p. 138-140°C;
- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-N'-(2-pyrid-2'-ylethyl)-L-prolinamide, m.p. 151-153°C;
- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-N'-(pyrid-2'-ylmethyl)-L-prolinamide, m.p. 108-110°C;
- (1S,3aS,7aR)-2-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-N'-t-butylcarboxamide, m.p. 97-100°C;
- (1R,3aR,7aS)-2-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-N'-t-butylcarboxamide, as an oil;
- (4R)-1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-4-hydroxy-N'-t-butyl-L-prolinamide, m.p. 122-124°C;
- (4S)-1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-4-hydroxy-N'-t-butyl-L-prolinamide, m.p. 123-124°C;
- (4R)-1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-4-t-butylcarbamoyloxy-N'-t-butyl-L-prolinamide, m.p. 114-116°C;
- (4S)-1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-4-t-butylcarbamoyloxy-N'-t-butyl-L-prolinamide, m.p. 127-128°C;
- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-N'-cyclohexyl-L-prolinamide, m.p. 120-122°C;
- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-N'-(2-(morpholin-4-yl)ethyl)-L-prolinamide, m.p. 126-128°C;
- 1-[(2S,3S)-3-(benzyloxycarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 204-205°C; and
- (3S,4aS,8aS)-2-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]decahydroisoquinoline-3-N'-t-butylcarboxamide, m.p. 113-115°C.
- D. In a similar manner, the following compounds were made:
- (2S)-1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy)l)amino-2-hydroxy-4-phenylbutanoyl]-2-N'-(pyrid-2-yl)-L-prolinamide, m.p. 140-142°C;
- (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-(1-benzylpiperidin-4-yl)carboxamide, m.p. 110-112°C;
- (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yl)oxy)ethanoyl-L-valyl)amino-

- 2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*iso*-propylcarboxamide, m.p. 108-110°C;
- (4*S*)-3-[(2*S*,3*S*)-3-(2-naphth-1-yloxy)ethanoyl-L-valylamino-2-hydroxy-4-phenylbutanoyl]thiazolidine-*N'*-*t*-butylcarboxamide, m.p. 154-155°C;
- 5 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 224-226°C;
- 1:1 mixture of (1*S*,3*aR*,7*aS*)-2-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-*N'*-*t*-butylcarboxamide and (1*R*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroisoindole-1-*N'*-*t*-butylcarboxamide;
- 10 1:1 mixture of (1*S*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-*N'*-*t*-butylcarboxamide and (1*R*,3*aR*,7*aS*)-2-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroisoindole-1-*N'*-*t*-butylcarboxamide, MS: 650.4 (MH)⁺;
- 15 (1*S*,3*S*,5*S*)-*N*-[(2*S*,3*S*)-3-benzyloxycarbonyl-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]-*endo*-2-azabicyclo[3.3.0]octane-3-*N'*-*t*-butylcarboxamide, m.p. 108-110°C;
- 20 (1*R*,3*R*,5*R*)-*N*-[(2*S*,3*S*)-3-benzyloxycarbonyl-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]-*endo*-2-azabicyclo[3.3.0]octane-3-*N'*-*t*-butylcarboxamide, m.p. 104-105°C;
- (3*S*,4*aR*,8*aR*)-2-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]decahydroisoquinoline-3-*N'*-*t*-butylcarboxamide, m.p. 114-117°C;
- 25 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-*trans*-3-phenyl-L-prolinamide, m.p. 208-210°C (more polar diastereomer) and 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-*trans*-3-phenyl-L-prolinamide, m.p. 144-146°C (less polar diastereomer);
- 30 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-*cis*-3-phenyl-L-prolinamide, m.p. 204-206°C (more polar diastereomer) and 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-*cis*-3-phenyl-L-prolinamide, m.p. 112-113°C (less polar diastereomer);
- 35 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-*trans*-3-ethyl-L-prolinamide, m.p. 191-192°C (more polar diastereomer) and 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-*trans*-3-ethyl-L-prolinamide,
- 40

- m.p. 108-112°C (less polar diastereomer);
 1-[(2*S*,3*S*)-3-(benzyl xycarbonyl-L-asparaginy]amin -2-hydroxy-
 4-phenylbutanoyl]-N'-t-butyl-cis-3-ethyl-L-prolinamide,
 m.p. 203-204°C (more polar diastereomer) and 1-[(2*S*,3*S*)-3-
 5 (benzyloxycarbonyl-L-asparaginy]amino-2-hydroxy-
 4-phenylbutanoyl]-N'-t-butyl-cis-3-ethyl-L-prolinamide,
 m.p. 104-106°C (less polar diastereomer);
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy]amino-
 2-hydroxy-4-(4'-hydroxy)phenylbutanoyl]octahydroindole-2-N'-t-
 10 butylcarboxamide, m.p. 146-148°C; and
 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy]amino-2-hydroxy-
 4-phenylbutanoyl]-5-ethyl-L-proline t-butyl ester, m.p. 106-107°C.
 E. EDCI (161 mg, 0.845 mmol) was added to a solution of HOBt (45 mg,
 0.338 mmol) and (2*S*,3*S*)-3-benzyloxycarbonyl-L-asparaginy]amino-2-hydroxy-4-
 15 phenylbutanoic acid (150 mg, 0.338 mmol) in dry DMF at 0°C and the resulting
 mixture was stirred at the same temperature for 20 min. A solution of
 (3*RS*,4*aRS*,8*aRS*)-decahydroisoquinoline-3-N'-t-butylcarboxamide (71 mg, 0.338
 mmol) in dry DMF was added. After stirring at room temperature for 16 hours,
 the solvent was removed in vacuo; the residue was taken up in ethyl acetate.
 20 The organic material was washed successively with water, 1*N* HCl and brine,
 dried over sodium sulphate and evaporated to give an oil which was
 chromatographed over 10% MeOH:CH₂Cl₂ to give (3*RS*,4*aRS*,8*aRS*)-2-[(2*S*,3*S*)-
 3-benzyloxycarbonyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]deca-
 hydroisoquinoline-3-N'-t-butylcarboxamide (110 mg), m.p. 127-130°C.

25

Example 2

Compounds of Formula (Ia) (As prepared by Reaction Scheme 3)

- A. A solution of benzyloxycarbonyl-L-N'-ethyl-asparagine (114 mg,
 0.389 mmol) and HOBt (60 mg, 0.389 mmol) in dry DMF (15 mL) was cooled to 0°C.
 30 EDCI (186 mg, 0.973 mmol) was added and the solution was stirred at 0°C for 55
 min. A solution of 1-[(2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-
 L-prolinamide (135 mg, 0.389 mmol) in dry CH₂Cl₂ (10 mL) was added and the
 mixture was stirred at room temperature for 24 hours. The solvent was removed
 in vacuo and the residue extracted with ethyl acetate and water. The organic
 35 layer was washed with 1*N* HCl, brine and dried over sodium sulphate. Solvent
 evaporation gave a solid which was purified by column chromatography (10%
 MeOH:CH₂Cl₂) and thick layer plate chromatography (10% MeOH:CH₂Cl₂) to give 1-
 [(2*S*,3*S*)-3-(benzyloxycarbonyl-L-N'-ethylasparaginy]amino-2-hydroxy-4-
 phenylbutanoyl]-N'-t-butyl-L-prolinamide (120 mg), m.p. 100-102°C;
 40 MS: 624.5(M+H)⁺.

B. In a similar manner, but replacing benzyloxycarbonyl-L-N'-
 ethylasparagine with the appropriate compound of formula (G), the f llowing
 compound of formula (Ia) was made:

1-[(2*S*,3*S*)-3-(t-butoxycarbonyl-L-N'-methylasparaginy]amino-2-hydroxy-

4-phenylbutanoyl]-N'-t-butyl-L-prolinamide; m.p. 118-120°C;

C. In a similar manner, the following compound was made:

(2S,3aS,7aS)-1-[(2S,3S)-3-(benzyloxycarbonyl-((2S)-ethylglycyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide, m.p. 219-220°C.

Example 3

Compounds of formula (Ib)

A. A solution of quinaldic acid (36 mg, 0.207 mmol) and HOBt (27 mg, 0.2 mmol) in dry DMF (15 mL) was cooled to 0°C under argon. EDCI (93 mg, 0.486 mmol) was added and the solution was stirred at 0°C for 20 minutes. A solution of 1-[(2S,3S)-3-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide (89 mg, 0.193 mmol) in dry CH₂Cl₂ was added and the resulting solution was stirred at room temperature for 24 hours in the dark. The solvent was removed in vacuo and the residue taken up with ethyl acetate. The organic layer was washed successively with water, sodium bicarbonate solution and brine, dried over sodium sulphate and evaporated to give an oil. The material was purified by column chromatography (80% acetone:hexane to acetone) and thick layer plate chromatography (10% MeOH:CH₂Cl₂) to give 1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide (45 mg), m.p. 129-130°C; recrystallized from CH₂Cl₂:hexane, MS: 617.3(M⁺), 600.1.

B. In a similar manner, but replacing 1-[(2S,3S)-3-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide with other compounds of formula (L), the following compounds of formula (Ib) were made: 1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-N'-ethylasparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 120-122°C; (2S,3aS,7aS)-1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide, m.p. 139-141°C; and (3S,4aS,8aS)-2-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]decahydroisoquinoline-3-N'-t-butylcarboxamide, m.p. 128-130°C.

C. In a similar manner, but replacing 1-[(2S,3S)-3-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide with 1-[(2S,3S)-3-L-valylamino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, the following compound of formula (Ib) was made: 1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide; m.p. 123-125°C.

D. In a similar manner, but replacing quinaldic acid with the appropriate compound of formula (M) and 1-[(2S,3S)-3-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide with the appropriate compound of formula (L), the following compounds of formula (Ib) were made: 1-[(2S,3S)-3-(2-(6-meth xynaphth-2-yl)ethan yl-L-asparaginyl)amino-2-hydroxy-

- 4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 113-115°C;
 (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide, m.p. 128-130°C;
- 5 1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]-amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 118-119°C;
 1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-N'-methylasparaginy]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 113-115°C;
 (2S)-1-[(2S,3S)-3-(4-bromobenzoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-piperidine-2-N'-t-butylcarboxamide, m.p. 122-124°C;
- 10 (4R)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-4-hydroxy-N'-t-butyl-L-prolinamide, m.p. 133-135°C;
 1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]-amino-2-hydroxy-4-phenylbutanoyl]-N'-(1-hydroxy-2-methylprop-2-yl)-L-prolinamide, m.p. 125-127°C;
- 15 (4R)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-4-ethoxy-N'-t-butyl-L-prolinamide, m.p. 114-115°C;
 1-[(2S,3S)-3-(2-(6-bromonaphth-2-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 114-115°C;
 1-[(2S,3S)-3-(2-(6-bromonaphth-2-yloxy)ethanoyl-L-valyl]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 135-137°C;
- 20 (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(6-bromonaphth-2-yloxy)ethanoyl-L-asparaginy]-amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide, m.p. 122-124°C;
 1-[(2S,3S)-3-(2-(1-bromonaphth-2-yloxy)ethanoyl-L-valyl]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 180-181°C;
 1-[(2S,3S)-3-(2-(naphth-2-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 122-123°C;
- 30 1-[(2S,3S)-3-(2-(naphth-2-yloxy)ethanoyl-L-valyl]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 203-204°C;
 1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide, m.p. 176-178°C;
- 35 (1S,3aS,7aR)-2-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroisindole-1-N'-t-butylcarboxamide, m.p. 132-134°C; and
 (1R,3aR,7aS)-2-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroisindole-1-N'-t-butylcarboxamide, m.p. 145-146°C.
- 40 E. In a similar manner, the following compounds were made:
 (2S,3aS,7aS)-1-[(2S,3S)-3-(benzoxazol-2-yl)-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide,

- m.p. 159-161°C;
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-(2*S*)-ethylglycyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 117-119°C;
 5 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-*L*-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 103-104°C;
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-*L*-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide,
 10 m.p. 130-132°C;
 (1*S*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-*N'*-*t*-butylcarboxamide, m.p. 141-144°C;
 (1*R*,3*aR*,7*aS*)-2-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-*N'*-*t*-butylcarboxamide, m.p. 144-146°C;
 15 (1*S*,3*aR*,7*aS*)-2-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-*N'*-*t*-butylcarboxamide, m.p. 125-128°C;
 20 (1*R*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-*N'*-*t*-butylcarboxamide, m.p. 123-125°C;
 (1*S*,3*S*,5*S*)-*N*-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-*N'*-*t*-butylcarboxamide, m.p. 109-110°C;
 25 (1*R*,3*R*,5*R*)-*N*-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-*N'*-*t*-butylcarboxamide, m.p. 125-128°C;
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-phenoxyethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide,
 30 m.p. 116-118°C;
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-(4'-hydroxy)phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 210-212°C (decomp.);
 35 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(pyrid-2-yloxy)ethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-(4'-hydroxy)phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 148-150°C;
 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(3-(morpholino-4-ylmethyl)phenoxy)ethanoyl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 108-110°C;
 40 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(benzimidazol-5-yl-*L*-asparaginylyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide, m.p. 108-110°C;

F. A solution of (3*RS*,4*aRS*,8*aRS*)-2-[(2*S*,3*S*)-3-benzylloxycarbonyl-*L*-

asparaginylamino-2-hydroxy-4-phenylbutanoyl]decahydroisoquinoline-3-N'-t-butylcarboxamide (110 mg, 0.183 mmol) in absolute ethanol was hydrogenated over 10% Pd/C for 6 hours. The catalyst was filtered through Celite under suction, the filtrate was evaporated to give (3RS,4aRS,8aRS)-2-[(2S,3S)-3-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]decahydroisoquinoline-3-N'-t-butylcarboxamide as an oil. Without any further purification, EDCI (48 mg, 41 mmol) was added to a solution of quinaldic acid (24.5 mg, 0.163 mmol) and HOBT (22 mg, 0.163 mmol) in dry DMF at 0°C. After 20 min., a DMF solution of (3RS,4aRS,8aRS)-2-[(2S,3S)-3-L-asparaginylamino-2-hydroxy-4-phenylbutanoyl]-decahydroisoquinoline-3-N'-t-butylcarboxamide was added and the mixture was stirred at room temperature overnight. The solvent was removed *in vacuo*, the residue was taken up in ethyl acetate. The organic mixture was washed successively with 1N HCl, brine, and dried over sodium sulphate. Solvent evaporation gave a product as a solid which was further purified by column chromatography (10% MeOH: CH₂Cl₂) to give (3RS,4aRS,8aRS)-2-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginylamino)-2-hydroxy-4-phenylbutanoyl]-decahydroisoquinoline-3-N'-t-butylcarboxamide as a white solid, I.R. (KBr): 3340, 1660-1680 cm⁻¹.

Example 4

(Compounds of Formula (Ib) wherein R¹ is optionally substituted substituted carbamoyl)

A. A solution of 2-aminomethylpyridine (5 g, 46 mmol) in CH₂Cl₂ (5 mL) was added to a solution of di-t-butylidicarbonate (10.2 g, 97%, 45.33 mmol) in CH₂Cl₂ (80 mL) at 0°C. The reaction mixture was stirred at 0°C for 2 hours, and then warmed up to room temperature overnight. The mixture was extracted with water (2 X 50 mL), dried over sodium sulphate and evaporated to give a yellowish oil (9.1 g). A portion of this material (8.1 g, 38.9 mmol) was dissolved in THF at 0°C. NaH (2.1 g, 52.5 mmol) was added and the mixture was stirred for 15 minutes. Methyl iodide (6.8 g, 47.9 mmol) was added. After stirring for 90 minutes, the reaction was quenched with ice and evaporated to give an oil. The residue was extracted between ether and water, dried over sodium sulphate and evaporated to yield N-(t-butoxycarbonyl)-N-methyl-N-(pyrid-2-ylmethyl)amine, as an oil (6.5 g).

B. Proceeding, N-(t-butoxycarbonyl)-N-methyl-N-(pyrid-2-ylmethyl)amine (2 g, 9.0 mmol) was added to a saturated solution of HCl gas in dry CH₂Cl₂. After 45 minutes, the solution was diluted with CH₂Cl₂ (100 mL) and basified to pH 10 by the slow addition of triethylamine. The solution was extracted with water, dried over sodium sulphate and evaporated to give N-methyl-N-(pyridin-2-ylmethyl)amine a white solid (1.06 g). Diphenylene (4 g, 20.2 mmol) was added to dry ethyl acetate (15 mL) at room temperature. A solution of valine methyl ester (3.96 g, 23.6 mmol) was added dropwise. An exothermic reaction took place and the mixture was stirred for 3 hours. Solvent evaporation gave a solid which was pumped to constant weight. This material was chlorocarbonyl-valine methyl ester. Without further

purification, this material (0.99 g) was mixed with a solution of *N*-methyl-*N*-(pyrid-2-ylmethyl)amine (0.6 g) in ethyl acetate (12 mL). After 18 hours at room temperature the filtrate was diluted with ethyl acetate and extracted with saturated sodium bicarbonate solution. The organic extract was washed
5 with brine, dried over sodium sulphate, and evaporated to give an oily residue. This material was chromatographed on silica gel (75% ethyl acetate:hexane) to give *N*-methyl-*N*-(pyrid-2-ylmethyl)carbamoyl-valine methyl ester (0.38 g).

C. Proceeding, NaOH solution (0.5 mL, conc.: 100 mg solid NaOH/mL
10 water, 1.25 mmol) was added to a solution of *N*-methyl-*N*-(pyrid-2-ylmethyl)carbamoyl-valine methyl ester (0.308 g, 1.1 mmol) in dioxane (8 mL) and water (4 mL) at 0°C. After 2 hours, the mixture was stirred at room temperature for 1 hour and neutralized to pH 7 with the addition of two drops of conc. HCl. The material was evaporated to dryness to give *N*-methyl-*N*-
15 (pyrid-2-ylmethyl)carbamoyl-valine sodium salt as a foam (0.33 g).

D. Proceeding, a solution of *N*-methyl-*N*-(pyrid-2-ylmethyl)carbamoyl-valine sodium salt in dry DMF (65 mg, 0.26 mmol) was mixed with EDCI (190 mg, 1 mmol) and HOBT (51 mg, 0.33 mmol) at 0°C. After 1 hour, a solution of
20 (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide (102 mg, 0.24 mmol) in dry DMF (4 mL) was added. After stirring for 16 hours, the solution was evaporated to dryness under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic extract was washed with saturated sodium bicarbonate solution, brine, dried over sodium sulphate and evaporated to give an oil. The material was
25 purified by column chromatography (5% MeOH:ethyl acetate) to give (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(*N'*-methyl-*N'*-(pyrid-2-ylmethyl)carbamoyl-*L*-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide (45 mg), m.p. 109-112°C.

30

Example 5

(Alternative Preparation of Compounds of formula (Ia))

A. A solution of 4-*t*-butoxycarbonylamino-1-benzylpiperidine (3.12 g, 10.7 mmol) in absolute ethanol was hydrogenated over 10% Pd(H)₂/C at 50 psi H₂ for 3 hrs. This catalyst was removed by suction filtration through Celite.
35 Solvent evaporation gave 4-*t*-butoxycarbonylamino-piperidine as a white solid (2.1 g), m.p. 159-161°C.

B. Proceeding, 4-*t*-butoxycarbonylaminopiperidine (1.45 g, 7.25 mmol) was added to a suspension of chlorocarbonyl-valine methyl ester (from Example 4B above, 0.73 g, 3.78 mmol) in ethyl acetate (30 mL). The material was
40 stirred for 20 hours, at room temperature. The insoluble white solid was filtered. The filtrate was extracted with ethyl acetate and saturated sodium bicarbonate. The organic extract was washed with brine, dried over sodium sulphate and evaporated to give an oil. The material was chromatographed on silica gel (2% MeOH:ethyl acetate) to give (4-(*t*-butoxycarbonylamino)piperid-
45 1-yl)carbamoyl-valine methyl ester as an oil (0.39 g). Part of this material (200 mg) was mixed with dioxane (8 mL) and water (4 mL) at 0°C. NaOH solution

(0.5 mL, conc.: 53 mg NaOH/mL water) was added. The mixture was stirred at 0°C for 2 hours and room temperature for 10 hours. The solution was neutralized to pH 7 with 6N HCl and evaporated to dryness. The solid residue was azeotroped with acetonitrile and pumped to constant weight (188 mg). This material was crude (4-(*t*-butoxycarbonylamino)piperid-1-yl)carbonyl-valine sodium salt, m.p. 110-113°C.

C. Proceeding, (4-(*t*-butoxycarbonylamino)piperid-1-yl)carbonyl-valine sodium salt (154 mg) was coupled to (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide (136 mg, 1.31 mmol) in the same manner as described in Example 4D above to give (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-((4-(*t*-butoxycarbonylamino)piperid-1-yl)carbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide. The product was isolated by column chromatography (75% ethyl acetate:hexane to 100% ethyl acetate), to yield 46 mg, m.p. 149-151°C.

D. Proceeding, (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-((4-(*t*-butoxycarbonyl-amino)piperid-1-yl)carbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide (44 mg, 0.06 mmol) from above was added to a solution of CH₂Cl₂ (20 mL) presaturated with HCl gas. The mixture was stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure. Ether was added and the insoluble solid was filtered to give (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-((4-aminopiperid-1-yl)carbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide hydrochloride (24 mg), m.p. 210-212°C.

Example 6

Oxidation of Compounds of Formulae (Ia) and (Ib)

A. Pyridinium dichromate (360 mg, 0.98 mmol) was added to a solution of 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide (100 mg, 0.173 mmol) in CH₂Cl₂ (10 mL) and DMF (2 mL). The solution was stirred at room temperature for 6 hours. The material was poured onto ice-cold water and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over sodium sulphate, and evaporated to give an oil. The material was purified by column chromatography (10% MeOH:CH₂Cl₂) and then reverse phase HPLC (CH₃CN:50 mM NH₄OAc buffer) to give [(3*S*)-(benzyloxycarbonyl-L-asparaginyl)amino-2-oxo-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide as a solid (10 mg), m.p. 85-87°C; MS: 594(M+H)⁺.

B. Alternatively, EDCI (198 mg, 0.1 mmol) was added to a mixture of toluene (4 mL) and DMSO (1 mL). After 15 minutes, 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide (100 mg, 0.173 mmol) and CF₃COOH (0.1 mL) was added. The mixture was stirred at room temperature for 24 hours, and then diluted with ethyl acetate (50 mL). The solution was washed five times with water (10 mL each time), dried over sodium sulphate and evaporated to give an oil. The material was purified by reverse phase HPLC (CH₃CN:50 mM NH₄OAc buffer) to give [(3*S*)-(benzyloxycarbonyl-L-asparaginyl)-amino-2-hydroxy-4-phenylbutanoyl]-*N'*-

t-butyl-L-prolinamide as a solid (20 mg), m.p. 85-87°C, MS: 594(M+H)⁺.

C. In a similar manner, but replacing 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyloxy)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide with [(2*S*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide, a compound of formula (N), the following compound was made:
[(3*S*)-3-benzyloxycarbonylamino-2-oxo-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide, as a foam.

10

Example 7

Reequilibration of Enantiomers

Lithium diisopropylamide (0.53 mL, 0.81 mmol, 1.5 M solution in THF) was added to a solution of (2*S*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid methyl ester (110 mg, 0.323 mmol) in dry THF under argon at -78°C and the resulting solution was stirred for 10 minutes. Chlorotrimethylsilane (0.1 mL, 0.64 mmol) was added at -78°C. The mixture was stirred at the same temperature for 40 min., lithium diisopropylamide (0.53 mL, 0.81 mmol, 1.5 M solution in THF) was again added and the mixture was stirred at -78°C for another 45 minutes. The mixture was poured onto ice cold citric acid and extracted with ethyl acetate. The organic phase was washed with 3N HCl and brine, dried over sodium sulphate and evaporated to give an oil. The oil was loaded onto a silica gel column and left for 2 hours before elution with 30% ethyl acetate:hexane to give the two stereoisomers, (2*S*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid methyl ester and (2*R*,3*S*)-3-benzyloxycarbonylamino-2-hydroxy-4-phenylbutanoic acid methyl ester. H-NMR indicated the two stereoisomers were formed in about 1:1 ratio (80 mg).

30

Example 8

Preparation of an Acid Addition Salt of a Compound of Formula (I)

HCl gas is bubbled into a solution of 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyloxy)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-(2-(morpholin-4-yl)ethyl)-L-prolinamide (100 mg, 0.153 mmol) in methylene chloride (15 mL) for 5 minutes. The solution is stirred at room temperature for 10 minutes and evaporated to dryness. This gives 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyloxy)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-(2-(morpholin-4-yl)ethyl)-L-prolinamide hydrochloride as the product.

40

Example 9

Preparation of the Free Base from the Salt of a Compound of Formula (I)

A solution of 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginyloxy)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-(2-(morpholin-4-yl)ethyl)-L-prolinamide hydrochloride (100 mg, 145 mmol) in dry CH₂Cl₂ (20 mL) is mixed with triethylamine (0.021 mL, 145 mmol) and stirred at room temperature for 30

-54-

minutes. The solution is extracted with water, the organic layer is dried over sodium sulphate and evaporated to give 1-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-N'-(2-(morpholin-4-yl)ethyl)-L-prolinamide.

5

EXAMPLE 10

This example illustrates the preparation of representative pharmaceutical compositions for oral administration containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, e.g.,

10 (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide:

15	A. <u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of formula (I)	20.0%
	Lactose	79.5%
	Magnesium stearate	0.5%

The above ingredients are mixed and dispensed into hard-shell gelatin capsules containing 100 mg each, one capsule would approximate a total daily dosage.

20	B. <u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of formula (I)	20.0%
	Magnesium stearate	0.9%
	Starch	8.6%
	Lactose	79.6%
	PVP (polyvinylpyrrolidone)	0.9%

25 The above ingredients with the exception of the magnesium stearate are combined and granulated using water as a granulating liquid. The formulation is then dried, mixed with the magnesium stearate and formed into tablets with an appropriate tableting machine.

30	C. <u>Ingredients</u>	
	Compound of formula (I)	0.1 g
	Propylene glycol	20.0 g
	Polyethylene glycol 400	20.0 g
	Polysorbate 80	1.0 g
	Water	q.s. 100 mL

35 The compound of formula (I) is dissolved in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient quantity of water is then added with stirring to provide 100 mL of the solution which is filtered and bottled.

40	D. <u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of formula (I)	20.0%
	Peanut Oil	78.0%
	Span 60	2.0%

The above ingredients are melted, mixed and filled into soft elastic capsules.

45

EXAMPLE 11

This example illustrates the preparation of a representative pharmaceutical formulation for parenteral administration containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, e.g.,
 5 (2S,3aS,7aS)-1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginylo-amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide:

Ingredients

	Compound of formula (I)	0.02 g
	Propylene glycol	20.0 g
10	Polyethylene glycol 400	20.0 g
	Polysorbate 80	1.0 g
	0.9% Saline solution	q.s. 100 mL

The compound of formula (I) is dissolved in propylene glycol, polyethylene glycol 400 and polysorbate 80. A sufficient quantity of 0.9%
 15 saline solution is then added with stirring to provide 100 mL of the I.V. solution which is filtered through a 0.2 μ membrane filter and packaged under sterile conditions.

EXAMPLE 12

20 This example illustrates the preparation of a representative pharmaceutical composition in suppository form containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, e.g., (1S,3S,5S)-N-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginylo-amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-N'-t-butylcarboxamide:

25	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of formula (I)	1.0%
	Polyethylene glycol 1000	74.5%
	Polyethylene glycol 4000	24.5%

The ingredients are melted together and mixed on a steam bath, and
 30 poured into molds containing 2.5 g total weight.

EXAMPLE 13

This example illustrates the preparation of a representative pharmaceutical formulation for insufflation containing a compound of formula
 35 (I), or a pharmaceutically acceptable salt thereof, e.g., (1S,3aS,7aR)-2-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginylo-amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-N'-t-butylcarboxamide:

	<u>Ingredients</u>	<u>% wt./wt.</u>
	Micronized compound of formula (I)	1.0%
40	Micronized lactose	99.0%

The ingredients are milled, mixed, and packaged in an insufflator equipped with a dosing pump.

EXAMPLE 14

45 This example illustrates the preparation of a representative

-56-

pharmaceutical formulation in nebulized form containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, e.g., (1*S*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-L-asparaginy)amino-2-hydroxy-4-phenylbutanoyl]octahydroisoindole-1-*N'*-*t*-butylcarboxamide:

5	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of formula (I)	0.005%
	Water	89.995%
	Ethanol	10.000%

The compound of formula (I) is dissolved in ethanol and blended with water. The formulation is then packaged in a nebulizer equipped with a dosing pump.

EXAMPLE 15

This example illustrates the preparation of a representative pharmaceutical formulation in aerosol form containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, e.g., 1-[(2*S*,3*S*)-3-(benzyloxycarbonyl-L-asparaginy)amino-2-hydroxy-4-phenylbutanoyl]-*N'*-*t*-butyl-L-prolinamide:

20	<u>Ingredients</u>	<u>% wt./wt.</u>
	Compound of formula (I)	0.10%
	Propellant 11/12	98.90%
	Oleic acid	1.00%

The compound of formula (I) is dispersed in oleic acid and the propellants. The resulting mixture is then poured into an aerosol container fitted with a metering valve.

Example 16

(In vitro assay for inhibition of HIV protease activity)

HIV protease, as encoded in the BRU strain of HIV-1, was obtained from microbially expressed fusion protein, after refolding, autoproccessing and purification, and used to evaluate the potency of compounds of formula (I). The HIV protease-mediated hydrolysis of the peptidyl substrate, Val-Ser-Gln-Asn-(β -naphthyl)Ala-Pro-Ile-Val, was monitored by modification of the method described in Heimbach, J.C., Garsky, V.M., Michelson, S.R., Dixon, R.A.F., Sigal, I.S. and Darke, P.L., *Biochem. Biophys. Res. Commun.* (1989), Vol. 164, pp. 955-960. Stock solutions of compounds of formula (I) were prepared in dimethylsulfoxide.

Reactions were initiated by addition of 25 μ L of 120 pM HIV protease in 50 mM sodium acetate at pH 5.5 containing 10% glycerol, 1 mM dithiothreitol and 1 mg/mL bovine serum albumin to 75 μ L of 13.3 μ M substrate in 50 mM sodium acetate, pH 5.5 containing 1.33 M sodium chloride, 10% glycerol and 2.66% dimethylsulfoxide, with or without a compound of formula (I). The reaction mixtures were quenched after 30 minutes at 30°C by addition of 100 μ L of 12% acetic acid containing 100 μ M CBZ-tyrosine, an internal standard to facilitate quantitation of products by HPLC (Perkin-Elmer RP-C18 reverse phase; gradient

elution with 0.1% aqueous phosphoric acid/acetonitril mixtures, (80:20) to (50:50) over 5.5 minutes at 2.5 mL/min. Product peaks were detected with a Hewlett-Packard HP 1046A fluorescence detector, $\lambda(\text{excitation}) = 228 \text{ nm}$ and $\lambda(\text{emission}) = 336 \text{ nm}$. The IC_{50} values were calculated by fitting of data to the equation.

$$V = V_{\text{max}} / (1 + [I] / \text{IC}_{50})$$

wherein V is the observed rate of the reaction, V_{max} is the uninhibited reaction rate, $[I]$ is the concentration of the compound of formula (I) and IC_{50} is the concentration of the compound of formula (I) required to reduce protease activity by fifty percent.

Compounds of formula (I), when tested by this assay, demonstrated the ability to inhibit HIV protease activity as shown in the following table.

TABLE 1		
No.	Compound	$\text{IC}_{50} \text{ nM}$
15	1) (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide	1.1
20	2) 1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide	0.58
25	3) 1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginyl)-amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide	1.5
30	4) (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(6-bromonaphth-2-yloxy)ethanoyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide	5.8
35	5) (1S,3S,5S)-N-[(2S,3S)-3-(2-(naphth-1-yloxy)-ethanoyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-N'-t-butylcarboxamide	0.49
40	6) (1S,3aS,7aR)-2-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroisoindole-1-N'-t-butylcarboxamide	1.3
45	7) (1S,3S,5S)-N-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-N'-t-butylcarboxamide	2.3
50	8) (1S,3aR,7aS)-2-[(2S,3S)-3-(2-(naphth-1-yloxy)-ethanoyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroisoindole-2-N'-t-butylcarboxamide	0.26
55	9) (2S,3aS,7aS)-1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-N'-t-butylcarboxamide	1.3
60	10) (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)-ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-N'-t-butylcarboxamide	5.7
	11) (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)-ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-N'-iso-propylcarboxamide	3.6

Table 1 continued			
No.	Compound		IC ₅₀ nM
5	12) (2S,3aS,7aS)-1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-N'-t-butylcarboxamide		30.0
10	13) (2S,3aS,7aS)-1-[(2S,3S)-3-(2-phenoxyethanoyl-L-asparaginy)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-N'-t-butylcarboxamide		1.9
15	14) (2S,3aS,7aS)-1-[(2S,3S)-3-(N'-methyl-N'-(pyrid-2-ylmethyl)carbamoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide		25.0
	15) 1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide		4.3
20	16) 1-[(2S,3S)-3-(2-naphth-1-yloxy)ethanoyl-L-asparaginy)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide		1.3
	17) 1-[(2S,3S)-3-(2-naphth-1-yloxy)ethanoyl-L-asparaginy)amino-2-hydroxy-4-(4'-hydroxy-phenyl)butanoyl]octahydroindole-2-N'-t-butylcarboxamide		10.0
25	18) 1-[(2S,3S)-3-(2-naphth-2-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide		2.8

Example 17

30 (In vitro cell assay for inhibition of HIV activity)

A common feature of retrovirus replication is the extensive post-translational processing of precursor polyproteins by a virally encoded protease, such as HIV protease, to generate mature viral proteins required for virus assembly and function. Examples of these viral proteins are reverse transcriptase and p24 core antigen. The following assay measures the level of reverse transcriptase and p24 core antigen present in the growth medium after inoculation of cells with the virus and subsequent treatment with a compound of formula (I). A direct correlation may then be made between the level of reverse transcriptase or the level of p24 core antigen found in the growth medium and the amount of virus produced in the cell. The amount of virus remaining in the cell is a direct indication of the anti-viral activity of the compound tested.

The cells used in this assay were A301 (ALEX) cells, a continuous human T-cell line. The cell growth medium was RPMI-1640 (JR Scientific), supplemented with 5% fetal bovine serum (FBS, JR Scientific). The A301 cells were obtained from the NIH repository. The cells were infected with virus for 3 hours at 37°C in 5% CO₂ in air. Cells were also mock-infected at the same time to be used to detect cytotoxicity and to serve as cell controls. Compounds of formula (I) were solubilized in either growth medium or dimethyl sulfoxide, dependent upon solubility. Compounds of formula (I) were then serially diluted in 96-well plates. The final volume of the compounds in the test wells was 100 µL. After the 3 hour infection incubation, the cells were washed three times to remove unabsorbed virus. The infected cells and uninfected cells were then added to appropriate wells of the plates at a

concentration of 3.75×10^4 in 150 μ L. All plates were incubated for 7 days. A 100 μ L change of medium and compound was performed on Day 4. At the end of the 7 day incubation, the plates were evaluated for cytotoxicity and p24 core antigen and/or reverse transcriptase (RT) levels. The cytotoxicity of the compounds of formula (I) was evaluated by visual inspection using cell morphology and cell death as criteria. The p24 core antigen level was determined by ELISA using the DuPont p24 Core Antigen test kit according to the method specified by the manufacturer. Virus production was determined by RT levels.

The RT assay was performed as previously described in *Biochem. Pharmacol.* (1987), Vol. 36, pp. 4361-2 whereby an aliquot of supernatant was mixed with 3.2% Triton-X100[®] to disrupt and inactivate the virus. After a 30 minute incubation period at 37°C, the assay mixture was added to the Triton-X100[®] supernatant samples and incubated for 1 hour at 37°C. The assay mixture contained 201.0 mmol TRIS buffer (pH 8.0), 20.1 mmol MgCl₂, 603.0 mmol KCl, 20 mmol dithiothreitol, 0.02 μ g/mL Poly (A) (SIGMA), 0.0023 μ g/mL Oligo (dT) 12-18 (PHARMACIA), and 5.1 μ mol [³H]thymidine triphosphate (25 Ci/mmol, DuPont New England Nuclear). Aliquots were then spotted on DEAE paper, washed 3 times with a mixture of 5% trichloroacetic acid and 1% pyrophosphate, and fixed in 95% reagent grade ethanol. Radioactivity was measured using a liquid scintillation spectrophotometer, after adding 7 mL of ReadySafe[®] (Beckman) to each vial. The effective concentration 50% (EC₅₀) and effective concentration 90% (EC₉₀) were defined as the concentration of a compound at which the reverse transcriptase values or p24 levels were reduced by 50% or 90%, respectively, as compared to the reverse transcriptase value or level of p24 obtained from untreated virus control supernatant. These values were determined graphically.

Compounds of formula (I) demonstrated the ability to inhibit HIV production when tested by this assay.

Example 18

(In vitro cell assay for inhibition of HIV activity)

The following assay measures the level of p24 core antigen present in the cell-free supernatant after inoculation of cells with the virus and subsequent treatment with a compound of formula (I). As described above in Example 15 for reverse transcriptase, a direct correlation may be made between the level of p24 core antigen found in the supernatant and the amount of virus produced in the cell. The amount of virus remaining in the cell is a direct indication of the anti-viral activity of the compound tested.

The cells used were MT-2 cells, a continuous human T-cell line transformed with HTLV-1. The cell growth medium was RPMI-1640 (JR Scientific), supplemented with 5% fetal bovine serum (FBS, JR Scientific). The virus strain (HTLV-III_{sf}) and the MT-2 cells were all obtained from the NIH repository. The cells were infected with virus for 1.5 hours at 37°C in 5% CO₂ in air. Cells were also mock-infected at the same time to be used to

detect cytotoxicity and to serve as cell controls. Compounds of formula (I) were solubilized in dimethyl sulfoxide. The compounds were then serially diluted in 96-well plates. The final volume of the compounds in the test wells was 100 μ l. After the 1.5 hour infection incubation, the cells were washed three times to remove unadsorbed virus. The infected cells and uninfected cells were then added to appropriate wells of the plates at a concentration of 3.75×10^4 in 150 μ l. All plates were incubated for 72 hours. At the end of the 72 hours incubation, the plates were evaluated for cytotoxicity and p24 core antigen. The cytotoxicity of the test compounds was evaluated by visual inspection using cell morphology and cell death as criteria. The p24 core antigen level in the supernatants was determined by ELISA using the DuPont p24 Core Antigen test kit according to the method specified by the manufacturer.

The effective concentration 50% (EC_{50}) and effective concentration 90% (EC_{90}) were defined as the concentration of a compound of formula (I) at which the p24 levels were reduced by 50% or 90%, respectively, as compared to the level of p24 obtained from untreated virus control supernatant. These values were determined graphically.

Compounds of formula (I) demonstrated the ability to inhibit the production of HIV when tested by this assay as shown in the below table.

TABLE 2		
No.	Compound	EC_{50}/EC_{90} nM
25	1) (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide	5-38/35-140 10 determ'ns
30	2) 1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide	131/360
35	3) 1-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-N'-t-butyl-L-prolinamide	145/540
40	4) (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(6-bromonaphth-2-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide	65/140
45	5) (1S,3S,5S)-N-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-N'-t-butylcarboxamide	5.3-15/35-37 4 determ'ns
50	6) (1S,3aS,7aR)-2-[(2S,3S)-3-(quinol-2-ylcarbonyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-octahydroisindole-1-N'-t-butylcarboxamide	47/153
55	7) (1S,3S,5S)-N-[(2S,3S)-3-(benzyloxycarbonyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-N'-t-butylcarboxamide	78/151
	8) (1S,3aR,7aS)-2-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-octahydroisindole-2-N'-t-butylcarboxamide	18/144

Table 2 continued			EC ₅₀ /EC ₉₀ nM
No.	Compound		
5	9) (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(2 <i>S</i> ,3 <i>S</i>)-3-(quinol-2-ylcarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2- <i>N'</i> - <i>t</i> -butylcarboxamide		7-26/23-110 6 determ'ns
10	10) (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(2 <i>S</i> ,3 <i>S</i>)-3-(2-(naphth-1-yloxy)-ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2- <i>N'</i> - <i>t</i> -butylcarboxamide		7-36/33-120 4 determ'ns
15	11) (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(2 <i>S</i> ,3 <i>S</i>)-3-(2-(naphth-1-yloxy)-ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2- <i>N'</i> - <i>iso</i> -propylcarboxamide		6-110/35-160 5 determ'ns
20	12) (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(2 <i>S</i> ,3 <i>S</i>)-3-(quinol-2-ylcarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2- <i>N'</i> - <i>t</i> -butylcarboxamide		57/530
25	13) (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(2 <i>S</i> ,3 <i>S</i>)-3-(2-phenoxyethanoyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2- <i>N'</i> - <i>t</i> -butylcarboxamide		82/420
30	14) (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(2 <i>S</i> ,3 <i>S</i>)-3-(<i>N'</i> -methyl- <i>N''</i> -(pyrid-2-ylmethyl)carbamoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2- <i>N'</i> - <i>t</i> -butylcarboxamide		240/2,200
35	15) 1-[(2 <i>S</i> ,3 <i>S</i>)-3-(quinol-2-ylcarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]- <i>N'</i> - <i>t</i> -butyl-L-prolinamide		500/620
40	16) 1-[(2 <i>S</i> ,3 <i>S</i>)-3-(2-naphth-1-yloxy)ethanoyl-L-asparaginyl]-amino-2-hydroxy-4-phenylbutanoyl]- <i>N'</i> - <i>t</i> -butyl-L-prolinamide		90-103/140-150 2 determ'ns
45	17) 1-[(2 <i>S</i> ,3 <i>S</i>)-3-(2-naphth-1-yloxy)ethanoyl-L-asparaginyl)amino-2-hydroxy-4-(4'-hydroxy-phenyl)butanoyl]octahydroindole-2- <i>N'</i> - <i>t</i> -butylcarboxamide		360/1,420
50	18) 1-[(2 <i>S</i> ,3 <i>S</i>)-3-(2-naphth-2-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]- <i>N'</i> - <i>t</i> -butyl-L-prolinamide		146/534

Example 19

(cytotoxicity)

At the same time the supernatants were removed for p24 determinations in the above assay (see Example 18), the cell control wells were read for compound toxicity.

At each concentration of compound, the number of live cells in the control wells (no virus infection) were read and the number compared to the cell control wells (no compound and no virus). The following rating scale was used:

- 55
- 0 = no fewer cells than in the cell control
 - 1 = 0-25% fewer cells than in the cell control
 - 2 = 25-50% fewer cells than in the cell control
 - 3 = 50-75% fewer cells than in the cell control
 - 4 = 75-100% fewer cells than in the cell control

60


Partial toxicity was defined as the lowest concentration of compound tested at which there was any visual reduction in cell growth. Complete toxicity was

defined as the lowest concentration of compound tested at which a score of "4" was given for toxicity. For compound (2S,3aS,7aS)-1-[(2S,3S)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginyloxy)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-N'-t-butylcarboxamide, the partial toxicity was 10 μ M and the complete toxicity was >10 μ M.

While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

WHAT IS CLAIMED IS:

1. A compound of formula (I):



10 wherein:

R¹ is alkoxycarbonyl, aralkoxycarbonyl, optionally substituted
aralkanoyl, optionally substituted aroyl, optionally substituted
heterocyclylcarbonyl, optionally substituted aryloxyalkanoyl, optionally
substituted carbamoyl or optionally substituted heterocyclyloxyalkanoyl;

15 R² is hydrogen;

R³ is alkyl optionally substituted by hydroxy, carbamoyl,
monoalkylcarbamoyl, or dialkylcarbamoyl;


R⁴ is optionally substituted aryl or optionally substituted aralkyl;

R⁵ is hydrogen;

20 R⁶ is hydroxy; or

R⁵ and R⁶ together form oxo; and

R⁷ is selected from the group consisting of:



wherein

n is 0, 1 or 2;

40 each R¹⁴ is independently hydroxy, alkyl, alkoxy or phenyl; and

R¹⁰ is alkoxycarbonyl or optionally substituted carbamoyl;

as a single stereoisomer or as a mixture thereof; or a pharmaceutically
acceptable salt thereof.

- 45 2. A compound of Claim 1 wherein the carbon to which R⁴ is attached

-64-

is in the *S*-configuration and the carbon to which R⁵ and R⁶ are attached is in the *S*-configuration; and wherein

R¹ is aralkoxycarbonyl, optionally substituted aryloxyalkanoyl, optionally substituted carbamoyl or optionally substituted heterocyclylcarbonyl;

5 R³ is alkyl optionally substituted by carbamoyl;


R⁴ is optionally substituted aralkyl;

R⁵ is hydrogen;

R⁶ is hydroxy; and

R⁷ is selected from the group consisting of:

10



15

wherein

R¹⁰ is monoalkyl carbamoyl.

3. A compound of Claim 2 wherein:

20 R¹ is optionally substituted aryloxyalkanoyl;

R³ is 1-methylethyl or methyl substituted by carbamoyl; and

R⁴ is benzyl.


4. A compound of Claim 3 wherein:

25 R¹ is 2-(naphth-1-yloxy)ethanoyl;

R³ is methyl substituted by carbamoyl; and

R⁷ is

30



wherein R¹⁰ is *N*-*t*-butylcarbamoyl;

35 one of the stereoisomers of which is named, (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy]amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-*N'*-*t*-butylcarboxamide.

5. A compound of Claim 3 wherein:


40 R¹ is 2-(naphth-1-yloxy)ethanoyl;

R³ is methyl substituted by carbamoyl; and

R⁷ is

45

-65-




5

wherein R^{10} is *N*-*t*-butylcarbamoyl;

two of the stereoisomers of which are named, (1*S*,3*aR*,7*aS*)-2-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy)amino-2-hydroxy-4-phenylbutanoyl]-octahydroisoindole-1-*N'*-*t*-butylcarboxamide, and (1*S*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-asparaginy)amino-2-hydroxy-4-phenylbutanoyl]-octahydroisoindole-1-*N'*-*t*-butylcarboxamide.

6. A compound of Claim 3 wherein:
 R^1 is 2-(naphth-1-yloxy)ethanoyl;
 R^3 is 1-methylethyl; and
 R^7 is

20




wherein R^{10} is *N*-*t*-butylcarbamoyl or *N*-*iso*-propylcarbamoyl;
 two of the stereoisomers of which are named, (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-*N'*-*t*-butylcarboxamide, and (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-*N'*-*iso*-propylcarboxamide.

30

7. A compound of Claim 3 wherein:
 R^1 is 2-phenoxyethanoyl;
 R^3 is methyl substituted by carbamoyl;
 R^7 is

35



40

wherein R^{10} is *N*-*t*-butylcarbamoyl;
 one of the stereoisomers of which is named, (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(2-phenoxyethanoyl-L-asparaginy)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-*N'*-*t*-butylcarboxamide.

45


8. A compound of Claim 3 wherein:

R¹ is 2-(naphth-1-yloxy)ethanoyl;

R³ is methyl substituted by carbamoyl;

R⁷ is

5



10

wherein R¹⁰ is *N*-*t*-butylcarboxamide;

one of the stereoisomers of which is named, (1*S*,3*S*,5*S*)-*N*-[(2*S*,3*S*)-3-(2-(naphth-1-yloxy)ethanoyl-*L*-asparaginyloxy)amino-2-hydroxy-4-phenylbutanoyl]-2-azabicyclo[3.3.0]octane-3-*N'*-*t*-butylcarboxamide.

15

9. A compound of Claim 2 wherein:

R¹ is optionally substituted heterocyclylcarbonyl;

R³ is 1-methylethyl or methyl substituted by carbamoyl; and

R⁴ is benzyl.

20


10. A compound of Claim 9 wherein:

R¹ is quinol-2-ylcarbonyl;

R³ is methyl substituted by carbamoyl; and

R⁷ is

25



30

wherein R¹⁰ is *N*-*t*-butylcarbamoyl;

one of the stereoisomers of which is named, (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-*L*-asparaginyloxy)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-*N'*-*t*-butylcarboxamide.

35


11. A compound of Claim 9 wherein:

R¹ is quinol-2-ylcarbonyl;

R³ is methyl substituted by carbamoyl; and

R⁷ is

40



45 wherein R¹⁰ is *N*-*t*-butylcarbamoyl;

one of the stereoisomers of which is named, (1*S*,3*aS*,7*aR*)-2-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-L-asparaginy)amin -2-hydr xy-4-phenylbutanoyl]octahydr -iscindole-1-*N'*-*t*-butylcarboxamide.


5 12. A compound of Claim 9 wherein:

R^1 is quinol-2-ylcarbonyl; .

R^3 is 1-methylethyl; and

R^7 is

10



15 wherein R^{10} is *N*-*t*-butylcarbamoyl;

one of the stereoisomers of which is named, (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(quinol-2-ylcarbonyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]-octahydroindole-2-*N'*-*t*-butylcarboxamide.

20 13. A compound of Claim 2 wherein:

R^1 is optionally substituted carbamoyl;

R^3 is 1-methylethyl or methyl substituted by carbamoyl; and

R^4 is benzyl.


25 14. A compound of Claim 13 wherein:

R^1 is *N*-methyl-*N*-(pyrid-2-ylmethyl)carbamoyl;

R^3 is 1-methylethyl; and

R^7 is

30




35 wherein R^{10} is *N*-*t*-butylcarbamoyl;

one of the stereoisomers of which is named, (2*S*,3*aS*,7*aS*)-1-[(2*S*,3*S*)-3-(*N'*-methyl-*N'*-(pyrid-2-ylmethyl)carbamoyl-L-valyl)amino-2-hydroxy-4-phenylbutanoyl]octahydroindole-2-*N'*-*t*-butylcarboxamide.

40 15. Use of a compound of formula (I):

45

-68-



5

wherein:

R^1 is alkoxycarbonyl, aralkoxycarbonyl, optionally substituted
aralkanoyl, optionally substituted aroyl, optionally substituted
heterocyclylcarbonyl, optionally substituted aryloxyalkanoyl,
10 optionally substituted carbamoyl or optionally substituted
heterocyclyloxyalkanoyl;

R^2 is hydrogen;

R^3 is alkyl optionally substituted by hydroxy, carbamoyl,
monoalkylcarbamoyl, or dialkylcarbamoyl;

15 R^4 is optionally substituted aryl or optionally substituted aralkyl;


R^5 is hydrogen;

R^6 is hydroxy; or


R^5 and R^6 together form oxo; and

R^7 is selected from the group consisting of:


20



25



30



35

wherein

n is 0, 1 or 2;


each R^4 is independently hydroxy, alkyl, alkoxy or phenyl; and

R^{10} is alkoxycarbonyl or optionally substituted carbamoyl;

40 as a single stereoisomer or as a mixture thereof; or a pharmaceutically
acceptable salt thereof, for inhibiting HIV protease in a mammal.

16. A pharmaceutical composition useful for the inhibition of HIV
protease in mammals, which composition comprises a therapeutically effective
amount of a compound of formula (I):

45



5

wherein:

R^1 is alkoxycarbonyl, aralkoxycarbonyl, optionally substituted
aralkanoyl, optionally substituted aroyl, optionally substituted
heterocyclylcarbonyl, optionally substituted aryloxyalkanoyl,
10 optionally substituted carbamoyl or optionally substituted
heterocyclyloxyalkanoyl;

R^2 is hydrogen;

R^3 is alkyl optionally substituted by hydroxy, carbamoyl,
monoalkylcarbamoyl, or dialkylcarbamoyl;

15 R^4 is optionally substituted aryl or optionally substituted aralkyl;


R^5 is hydrogen;

R^6 is hydroxy; or


R^5 and R^6 together form oxo; and

R^7 is selected from the group consisting of:


20



25



30



35

wherein

n is 0, 1 or 2;

each R^{14} is independently hydroxy, alkyl, alkoxy or phenyl; and


R^{10} is alkoxycarbonyl or optionally substituted carbamoyl;

as a single stereoisomer or as a mixture thereof; or a pharmaceutically
40 acceptable salt thereof; and a pharmaceutically acceptable excipient.

17. A process for the preparation of a compound of formula (I):

45

-70-



5

wherein:

R¹ is alkoxycarbonyl, aralkoxycarbonyl, optionally substituted
aralkanoyl, optionally substituted aroyl, optionally substituted
heterocyclylcarbonyl, optionally substituted aryloxyalkanoyl, optionally
substituted carbamoyl or optionally substituted heterocyclyloxyalkanoyl;

10


R² is hydrogen;

R³ is alkyl optionally substituted by hydroxy, carbamoyl,
monoalkylcarbamoyl, or dialkylcarbamoyl;


R⁴ is optionally substituted aryl or optionally substituted aralkyl;

15 R⁵ is hydrogen;R⁶ is hydroxy; orR⁵ and R⁶ together form oxo; andR⁷ is selected from the group consisting of:


20



25



30



wherein

35


n is 0, 1 or 2;

each R¹⁴ is independently hydroxy, alkyl, alkoxy or phenyl; andR¹⁰ is alkoxycarbonyl or optionally substituted carbamoyl;

as a single stereoisomer or as a mixture thereof; or a pharmaceutically
acceptable salt thereof, which comprises

40

a) reacting a compound of the formula



45

wherein G_1 is an amino-protecting group selected from the group consisting of t-but xycarbonyl, 2-(naphth-1-yl xy)ethanoyl and benzyloxycarbonyl and R^2 , R^3 , and R^4 are as defined above, with a compound of the formula


5



wherein R^7 is as defined above, to form a compound of formula (I) wherein G_1 is as defined above; or

b) treating a compound of the formula

10




15 wherein R^2 , R^3 , R^4 , and R^7 are as defined above, with a compound of the formula



wherein R^1 is as defined above, to form a compound of formula (I); or


20

c) reacting a compound of the formula



25

wherein R^4 and R^7 are as defined above, with a compound of the formula



30

wherein G_1 , R^2 , and R^3 are as defined above and R^{16} is hydrogen or p-nitrophenyl, to form a compound of formula (I) wherein G_1 is as defined above; or

35

d) oxidizing a compound of formula (I) wherein R^5 is hydrogen and R^6 is hydroxy, to form a compound of formula (I) wherein R^5 and R^6 together form oxo; or

e) converting a compound of formula (I) to a pharmaceutically acceptable salt thereof; or

40


f) converting a pharmaceutically acceptable salt of a compound of formula (I) to the corresponding free compound of formula (I); or

g) converting a pharmaceutically acceptable salt of a compound of formula (I) to another pharmaceutically acceptable salt of a compound of formula (I).

45

18. The process of Claim 17, step a) or c), which process further comprises

- a) catalytically hydrogenating a compound of formula (I) wherein G, is an amino-protecting group selected from the group consisting of t-butoxycarbonyl, 2-(naphth-1-yloxy)ethanoyl and benzyloxycarbonyl and R², R³, R⁴, and R⁷ are as defined above, to form a compound of the formula



followed by

- b) treating a compound of formula (I) wherein R², R³, R⁴, and R⁷ are as defined above, with a compound of the formula




wherein R¹ is as defined above, to form a compound of formula (I); optionally followed by

- c) oxidizing a compound of formula (I) wherein R⁵ is hydrogen and R⁶ is hydroxy, to form a compound of formula (I) wherein R⁵ and R⁶ together form oxo; or
- d) converting a compound of formula (I) to a pharmaceutically acceptable salt thereof; or
- e) converting a pharmaceutically acceptable salt of a compound of formula (I) to the corresponding free compound of formula (I); or
- f) converting a pharmaceutically acceptable salt of a compound of formula (I) to another pharmaceutically acceptable salt of a compound of formula (I).

INTERNATIONAL SEARCH REPORT

PCT/US 92/10772

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5	C07D207/16; C07D211/60;	C07D209/42; C07D217/26;
	C07D209/44; C07D277/06;	C07D209/52 A61K31/40
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	EP,A,0 498 680 (SANKYO COMPANY, LTD.) 12 August 1992	1,15-18
P,Y	* Table 1 * see claims 1-26,39,42-47 ---	2-14
Y	EP,A,0 346 847 (F. HOFFMANN-LA ROCHE AG) 20 December 1989 * entire document * see claims 1-25 ---	1-18
P,Y	J. MED. CHEM. vol. 35, no. 7, 1992, pages 1318 - 1320 T.F. TAM ET AL. 'Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides' * entire document * --- -/--	1-18
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 06 MAY 1993		Date of Mailing of this International Search Report 25. 05. 93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer HERZ C.P. 

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	
Y	J. MED. CHEM. vol. 20, no. 47, 1977, pages 510 - 515 R. NISHIZAWA ET AL. 'Synthesis and Structure-Activity Relationships of Bestatin Analogues, Inhibitors of Aminopeptidase B' * entire document *	1-16
Y	--- CHEM. PHARM. BULL. vol. 39, no. 11, 1991, pages 3088 - 3090 T. MIMOTO ET AL. 'KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic' * entire document *	1-16
Y	--- CHEM. PHARM. BULL. vol. 39, no. 9, 1991, pages 2465 - 2467 T. MIMOTO ET AL. 'Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of Phenylnorstatine or allophenylnorstatine as a transition-state mimic' * entire document *	1-16

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9210772
SA 68307

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 06/05/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0498680	12-08-92	AU-A- 1081292	13-08-92
		CA-A- 2060844	09-08-92

EP-A-0346847	20-12-89	AU-B- 624144	04-06-92
		AU-A- 3613089	14-12-89
		JP-A- 2042048	13-02-90
		US-A- 5157041	20-10-92
